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CHAPTER I
INTRODUCTION

The spectrin superfamily is a group of proteins that have similar structural and
functional features. They are present in several tissues but have different names. Spectrin
is present in erythrocytes, dystrophin in muscle tissues, fodrin in brain and other tissues,
and a-actinin in skeletal, cardiac and smooth muscles (Dhermy, 1991; Winkelman and
Forget, 1993). It is named the spectrin superfamily since spectrin is the most studied
member of the family. It is the main component of a two dimensional network of proteins
called the erythrocyte membrane skeleton, that is underlying the surface of the erythrocyte
membrane (Marchesi and Steers, 1968; Branton et al., 1981; Gratzer, 1983; Gratzer,
1984; Bennett, 1990).
The erythrocyte membrane skeleton interacts with several integral membrane
proteins thus influencing the lateral mobility of these proteins (Goodman and Branton,
1978). Beside interacting with the integral proteins, the membrane skeleton interacts with
lipids in the membrane (Mombers et al., 1980; Maksymiw et al., 1987; Subarrao et al.,
1991). Through all these interactions, the membrane skeleton provides support to the lipid
bilayer so it can withstand the shear pressure that erythrocytes have to endure passing
through blood vessels. This support is essential for the survival of erythrocytes (Lux and
Glader, 1981; Marchesi, 1985; Elgsaeter and Mikkelson, 1991 ).
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Spectrin was purified for the first time from the erythrocyte membrane skeleton
in 1968 (Marchesi and Steers, 1968). Purified spectrin was found to constitute 25-30%
of the total erythrocyte membrane protein (Marchesi et al., 1971; Fairbanks et al., 1971 ;
Steck, 1974). When the purified spectrin was run on sodium dodecyl sulfate (SDS)
polyacrylamide gel electrophoresis (PAGE), it appeared on the gel as two bands with
apparent molecular weight of 260 kD for the first band and 225 kD for the second band.
Thus the two subunits of spectrin are often referred to as Band 1 and Band 2 (Steck,
1974), or as a- and P-spectrin.
Due to the large size and the shape of the spectrin molecule, it is difficult to apply
nuclear magnetic resonance (NMR) or X-ray crystallography to study its structure.
However, other techniques have been used to obtain structural and physical properties of
spectrin. For example, electron microscopy (Shotton et al., 1979) and sedimentation
velocity (Ralston and Dunbar, 1979), studies of spectrin suggest that spectrin heterodimer
is a 100 nm long, rod-like molecule with a diameter of 4-6 nm. Additional structural
information was obtained on negatively stained spectrin in the partially expanded
membrane skeleton, suggesting that the a- and P-spectrin subunits twist around each
other forming a two-stranded helix with a pitch of about 104-106

Aand a diameter of

about 36-52 A(McGough and Josephs, 1990). Circular dichroism (CD) (Ralston, 1976)
and Fourier transform infrared (FTIR) (LaBrake and Fung, 1993) studies suggest that
spectrin contains 60-75% a-helix.
Spin labeling electron paramagnetic resonance (EPR) studies showed different
types of motions (Fung et al., 1979; Cassoly et al., 1980; Dubreuil and Cassoly, 1983;

3

Fung and Johnson, 1983; Streichman et al., 1991; Hensley et al., 1993). The combination
of conventional and saturation transfer EPR methods was used to determine the motions
of these spin labels to be in the time ranges of 10-9, 10-1, 10-6 and 10-3 s (Fung et al., 1979;
Fung and Johnson, 1983). Dynamic light scattering was also used to study the segmental
motion of spectrin tetramer (Budzynski et al., 1992). It measured fluctuational segmental
motions over a distance of20-30 nm with relaxation times equal or less than 23 µs. These
studies show that spectrin is a highly flexible molecule, which is understandable since it
contributes to the deformability and elasticity properties of human erythrocytes.
The ex- and P-spectrin subunits interact side-to-side in an antiparallel manner to
form the spectrin dimer (Speicher et al., 1982). This interaction starts at a nucleation site
which is at the C-terminal end of the ex-subunit and the N-terminal end of the P-spectrin
followed by several interaction sites along the length of each of the two subunits (Speicher

et al., 1992). Two of the spectrin dimers can associate head-to-head (the N-terminal
region of the ex-subunit in one dimer interacting with the C-terminal region of the

P-

subunit on the other dimer) to form the spectrin tetramer (Ungewickell and Gratzer, 1978;
DeSilva et al., 1992; Speicher et al., 1993), which is the predominant form in erythrocytes
(Byers and Branton, 1985; Liu et al., 1987). Diseases that are associated with abnormal
red blood cell shape such as hereditary elliptocytosis and hereditary pyropoikilocytosis
were found to have deficiency in spectrin tetramer and to be caused by mutations in the
N-terminal region of the ex-spectrin (Boulanger et al., 1994; Gallagher et al., 1992;
Lecomte et al., 1989) or in the C-terminal region of the P-spectrin (Gallagher et al., 1995;
Sahr et al., 1993; Tse et al., 1990) subunits. Most of the mutations in the ex-spectrin
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subunit were found to be within the first 150-200 amino acid residues. These mutations
were suggested to destabilize the head-to-head interactions and thus the tetramer
formation. Binding constants of spectrin dimers to give tetramer at 3 7 C was about 2 x
10 5 M- 1 (Ungewickell and Gratzer, 1978; DeSilva et al., 1992).
Recombinant a-spectrin peptides were used to study the domain structure and their
binding with (3-spectrin, to understand the role of spectrin in maintaining the biconcave
shape of normal erythrocyte.
The amino acid sequence of the a- and f3-spectrin subunits showed that both
subunits contain homologous amino acid sequences of about 106 reisdues long (Sahr et

al., 1990; Winkelman et al., 1990). The first 150-200 amino acid residues contain such
homologous sequence. The presence of these homologous sequences suggested the
presence of structurally stable domains and the structure of a- and P-spectrin subunits to
be as a string of structural domains. Thus studies of the structure of these homologous
sequences are essential in solving the structure of the part of molecule containing the first
150-200 amino acid residues, and of the entire molecule.
The presence of structural domains within the homologous sequence led to the
question of where is the start of the domain structure? For example, in the sequence
ABCDEFABCDEFABCDEF, a domain of 6 letters could start with the letter A and the
domain would be ABCDEF, at Band the domain would be BCDEFA, or at C and the
domain would be CDEFAB. Thus six different possibilities appear for a six letter domain,
and about 106 different possibilities for spectrin domains. Assuming that folded domains
will be digested slower that the non-folded part, various fragments of spectrin were
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prepared by recombinant techniques and subjected to digestion by proteases. Protease
products were separated for N-terminal sequencing to determine the start of the domain.
The first amino acid residue in the structural domain was determined to be 26 amino acid
residues downstream from the beginning of the sequence motif for Drosophila a -spectrin
(Winograd et al., 1991). Assuming that human a-spectrin has the same phase shift as

Drosophila a-spectrin, the first amino acid residue in the first structural repeat would be
amino acid residue number 49.

Another study suggested that the start of the first

structural repeat is amino acid residue number 54 (Speicher et al., 1993). However, the
start of human a-spectrin is not clear.
Based on the findings that spectrin is highly helical, the length of the spectrin
subunits of 100 nm is approximately one third the length of an a-helix of 2, 000 amino acid
residues, the amino and carboxy termini of the subunits are located opposite to each other

in the spectrin molecule, and spectrin is more flexible in solution than coiled-coil a-helical
proteins, a triple a-helical bundle was suggested as the structure for the 106 amino acid
sequence (Speicher and Marchesi, 1984). A modification of the above model showing the
three helices (A, B and C), with the last helix (C) in the nth repeat and the first helix (A)
in (n + l)th repeat forming a one long helix (CA) (Parry and Cohen, 1991; Parry et al.,
1992). X-ray crystallography of a folded domain from Drosophila a-spectrin supports
this model (Yan et al., 1993).
In this study, various recombinant a-spectrin peptides were used to study the N-

terminal region of a-spectrin that is important in the binding of P-spectrin.
In the first part of this study, 8 peptides with different lengths were expressed and
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purified. Limited protease digestion combined with amino acid sequencing were used to
determine the start of the first structural domain of the cx-spectrin subunit. This work, in
collaboration with other members in our laboratory, was published in 1994 (see
Appendix).
In the second part of the study, two different cx-spectrin peptides and P-spectrin

subunit were prepared for binding studies. Three different techniques--Superose 6 size
exclusion gel chromatography, combined radiolabeling with western blotting and
immunoprecipitation of radiolabeled peptides--were used to obtain binding constants.
These binding constants were shown to be comparable with spectrin dimer-dimer binding
constants, suggesting that these cx-spectrin peptides are good model systems for cx-spectrin
subunit studies.

CHAPTER II
MATERIALS AND METHODS

2.1

Chemicals and Equipment
All general chemicals were obtained from Sigma chemical Company (St. Louis,

MO), Curtin Matheson Scientific, Inc. (Wooddale, IL), or Fisher Scientific (Pittsburgh,
PA). Specific chemicals such as 4-maleimido-2,2,6,6-tetramethyl-l-piperidinyloxy (Mal6)
was obtained from Aldrich Chemical Company Inc. (Milwaukee, WI); Ampicillin and
glutathione Sepharose 4B resin from Pharmacia Biotechnology (Piscataway, NJ); protein
molecular weight standards from Gibco BRL Life Technologies Inc. (Gaithesburg, MD);
dye reagent for protein assay from Bio-Rad (Richmond, CA); isopropyl-B-Dthiogalactoside (IPTG) from Promega Company (Madison, WI);
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I from ICN (Costa

Mesa, CA). cDNA of spectrin was a generous gift from Dr. B. G. Forget of Yale School
of Medicine, New Haven, CT. All equipment were available in our laboratory with the
exception of the gamma counter which is in the Department of Biology.

2.2

Cloning and Expression of a-Spectrin Peptides

2.2.1

DNA Preparation
Sense and antisense oligonucleotide pnmers were synthesized by National
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Biosciences (Plymouth, MN). The primers were dissolved in deionized water by heating
to 65 °C for IO minutes to give a final concentration of 100 pmole/ µl. The solution was
stored in aliquot at -70°C to avoid repeated freezing and thawing. A 200 µl PCR cocktail
was prepared by adding 2 µl of the sense oligonucleotide, 2 µl of the antisense
oligonucleotide, 10 µl of 20X buffer (supplied by the company), 4 µl of 10 mM dTNPs,
179 µl of sterile deionized water, 2 µl of template (cDNA clone a3), and finally 1 µl of

Taq polymerase in a 1.5 ml microfuge tube. The tube was placed in a thermal cycler
(Eppendorf Microcycler) and 1 parafilm bead added to the mixture. The PCR was
programmed to run 35 cycles of30 seconds at the denaturation temperature (95°C), 45
seconds at the annealing temperature (calculated using the equation Tm = 4 x ( G or C) +
2 x (A or T), where G,C,A and Tare the number of deoxyguanylate, deoxycytidylate,
deoxyadenylate and deoxythymidylate in the primers, respectively), and 60 seconds at the
polymerization temperature (72°C). 10 µl of the resulting mixture was loaded on an
agarose gel to check if the expected DNA piece was made. A standard of 100 bp was
loaded on the adjacent well to check if the DNA piece has the correct length. Then the
Promega magic PCR prep DNA purification system (Promega, Madison, WI) was used
to purify the DNA piece out of the mixture giving 50 µl of DNA solution.
2.2.2

DNA Agarose Gel Electrophoresis
To purify DNA fragments, 1% agarose gels were prepared. 0.5 g of agarose was

added to 50 ml of TBE buffer (89 mM Tris, 89 mM boric acid, 2 mM EDT A) and
dissolved by boiling the solution. The solution was stirred until it cooled down and
ethidium bromide was added to give a final concentration of0.5 µglml (2.5 µl of 10 mg/ml
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stock solution). After solution cooled down further, it was poured into a horizontal gel
cast. After gel hardened at room temperature, the cast was moved to the gel chamber and
TBE buffer added. DNA samples were prepared by adding a 2X loading buffer containing
a tracing dye (orange G). Gel samples were loaded onto the gel and electrophoresis ran
under constant voltage of 50 V until desired separation was reached. The separation was
followed using a MINERALIGHT LAMP (UVP INC, San Gabriel, CA).
2.2.3

Spectrin Construct Preparation
Ten ml of overnight culture of cells containing the pGEX-2T vector were pelleted

down and the supernatant decanted. The Promega magic PCR prep DNA purification
(Promega, Madison, WI) system was used to give a 50 µl purified vector solution. 2 µl
was electrophoresed on an agarose gel to check the presence of the vector.
The purified DNA pieces and the pGEX-2T vector were digested by incubating 20
µl of each with 5 µl of buffer 3 (IOX, supplied by the company), 1 µl ofEcoRI, lµl of
BamHI and deionized water to 50 µl in a water bath at 37°C for 2 hours. The cut DNA
pieces and vector were purified on an agarose gel by excising the desired bands off the gel
followed by extraction of the DNA from the excised bands.

The gel bands were

transferred to 0.5 ml microfuge tube containing glass wool and has a hole at the bottom.
The microfuge tube was placed in a 1. 5 ml microfuge tube and centrifuged at 2, 000 g for
10 minutes. The 0.5 ml microfuge tube was discarded. The DNA was further purified by
phenol extraction. O.SX the DNA solution volume of phenol was added and the solution
was spun for 2 minutes in a picofuge. To the phenol layer (upper layer), O.SX the volume
of chloroform was added and the tube spun for 2 minutes in a picofuge. To the aqueous
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layer, o. l X the volume of 3M sodium acetate, 2X the volume of 100% ethanol and 2 µg
of yeast tRNA (for vector only) were added. The mixture was incubated on dry ice for 1520 minutes followed by spinning the tube for 20 minutes at 15, 000 g. After decanting the
supernatant, the pellet was washed with 200 µl of 70% ethanol and spun for 5 minutes at
15,000 g. The solution was dried by heating at 65°C for 5 minutes. Ten µl of 10 mM
Tris, 0.1 mM EDTA, pH 8.0 was added to the tube and heated at 65 °C for 5 minutes. 4
µl of the final solution was electrophoresed on an agarose gel to check the purity of the
samples.
Two µl of the vector and comparable amount of the DNA piece were combined
in a microfuge tube along with 1 µl ofT4 DNA ligase (Epicenter Technologies, Madison,
WI), 1. 5 µl of the 10 X buffer (supplied with the ligase), 1 µl of ATP and deionized water
to 15 µl. The mixture was incubated at 15 ° C overnight followed by a second incubation
at 65 °C for 10 minutes to deactivate the ligase.
A mixture of 100 µl HB 101 competent cells and 5 µl plasmid were mixed and
incubated on ice for 30 minutes. Then 300 µl of TSS (0.5% sodium chloride, 1%
tryptone, 0.5% yeast extract, 10% PEG, 5% DMSO, and 50 mM magnesium chloride)
buffer was added and the mixture was incubated with shaking for 60 minutes. The cells
were poured and smeared on an agar plate and the agar plates were left overnight at 3 7 ° C.
Colonies were tested for correct transformation as described below in section 2.3.1.
Colonies producing fusion proteins were then smeared on agar plates and incubated
overnight at 37°C. The agar plates were kept for up to 1 month afterwhich the cells were
smeared on a new agar plate.
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Cells containing plasmids of all the peptides used in this project were prepared by
Dr. M.R. Kelley either while he was at Loyola Medical School or while he is at Riley
Hospital for Children , University oflndiana , Indianapolis, IN. Cells prepared by Dr. M.
R. Kelley include Spa 1-166(S12C) with the serine residue at position 12 replaced with

cysteine.

2.3

Expression, Purification and Digestion of GST-Fusion Proteins

2.3.1

Testing Cells For The Ability to Express Fusion Proteins
Cells were inoculated (-4:30 p.m.) into two test tubes each containing 2 ml of

autoclaved medium (prepared as described in section 2.3.2 below) and Ampicillin added
to a final concentration of 0 .1 mg/ml. The cells were incubated overnight at 3 7 °C with
shaking at 225 rpm. At 9:00 a.m. the following day, 100 µl aliquot of each of the test
tubes was added to another test tube containing 1. 9 ml of autoclaved medium and
Ampicillin added to a final concentration of 0.1 mg/ml. At 11 :30 a.m., isopropyl-P-Dthiogalactoside (IPTG, Pharmacia Biotechnologies, Piscataway, NJ) was added to one of
the two test tubes to a final concentration of 0.1 mM. At 3 :30 p.m., cells were harvested
by removing 1. 5 ml from each test tube to a microfuge tube. The microfuge tubes were
centrifuged for 5 minutes at 15000 xg and the supernatant discarded.

100 µl of

electrophoresis sample buffer was added to the pellet, mixed, and boiled for 5 minutes.
The two samples, with and without IPTG, were ran side to side on a gel to determine
whether fusion protein was induced in sample containing IPTG.
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2.3 .2

Cell Growth
Medium was prepared by dissolving IOg/L oftrypton, Sg/L of yeast extract, and

Sg/L NaCl in water and autoclaved. Cells were inoculated in autoclaved medium (4-S
p.m.) and Ampicillin added to a final concentration of 0.1 mg/ml. The cells were left to
grow overnight at 37°C with shaking at 22S rpm. At 9:00 a.m. (O.D.
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=

-2) the cells

were diluted 1:20 in autoclaved medium and ampicillin added to a final concentration of
0.1 mg/ml. The solution was left at 37°C with shaking at 200 rpm for 2.S hours. At
11:30 a.m. (O.D.(>(J() = O.S-1, the mid-log phase), IPTG was added to a final concentration
of 0.1 mM. The solution was left at 37°C with shaking at 200 rpm for 4 hours (3 :30 p.m.,
O.D.(>(J() = -2). Cells were harvested by centrifuging the resulting solution at SOOO rpm for
10 minutes in a Sorvall RC-SB Refrigerated Superspeed Centrifuge (Du Pont Instruments,
Wilmington, DE) with GSA rotor. Cells, if not used, were stored at -70 ° C until needed.
2. 3. 3

Fusion Protein Purification
Cells, if frozen were thawed at 4 °C for l S-30 minutes and S-10 ml of 1% Triton

X-100 in PBS were added per gram of cells. They were lysed either by sonication or by
freeze-thaw followed by sonication. Cell lysate was centrifuged at 10,000 rpm for 10
minutes in a Sorvall RC-SB centrifuge with SS34 rotor. The supernatant was collected
and loaded on a glutathione affinity column pre-equilibrated with phosphate buffered saline
at pH 7.4 (PBS7.4). After incubating the supernatant on the column for 5 minutes, it was
eluted out of the column by free flow. The column was washed with PBS7.4 buffer until
the absorbance at 280 nm decreased below 0.020. After that, the column was washed with
SO mM Tris pH 8.0 buffer containing S mM fresh glutathione. The peak containing the
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fusion protein was collected and concentrated using Stirred Cells with PMlO Disc
Membranes (Amicon, Beverly, Mass).
2.3.4

GST Purification
Same procedure as above except E. coli cells containing the pGEX-2T vector

rather than modified vectors were used to get GST rather than GST-spectrin fusion
protein.

2.4

Purification of a-Spectrin Peptides

2.4.1

Thrombin Cleavage of Fusion Proteins
In order to determine the optimum incubation time that would produce maximum

digestion and minimum degradation of the spectrin peptide, a time study was performed.
The concentrated protein was dialyzed against 50 mM Tris, 10 mM EDTA pH 8.65
buffer. The concentrated and dialyzed protein was loaded onto a thrombin column
(thrombin covalently linked to agarose beads, CalBiochem, San Diego, CA) with up to 50
mg of fusion protein per 1 ml of resin and SDS-PAGE samples were taken every several
hours. 24 hours incubation at room temperature was found to be sufficient. The mixture
of GST, spectrin peptide and residual fusion protein was eluted out of the column.
2.4.2

Affinity Purification of a-Spectrin Peptides
The eluted mixture from the thrombin column was loaded onto a glutathione

affinity column pre-equilibrated with PBS7.4 buffer. The spectrin peptide was eluted by
washing the column with PBS7.4 buffer. GST and residual fusion protein were removed
by washing the column with 50 mM Tris pH 8.0 buffer containing 5 mM fresh glutathione.
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The spectrin peptide solution was concentrated using Stirred Cells and YM3 Disc
Membranes.
2.4.3

FPLC Purification
The FPLC system (Pharmacia Biotechnologies, Piscataway, NJ) contains two P-

500 pumps (A and B), LCC-500 controller, Single Path Monitor UV-1 optical unit,
FRAC-100 fraction collector, and a chart recorder. Hemoglobin purified by ion-exchange
chromatography was used as a reference sample to check column performance. A salt
gradient was created by using two buffers: the first was 10 mM Tris, pH 7.8 with no salt
while the second was 10 mM Tris, pH 7.8 with 1 M NaCl. Frozen hemoglobin was
thawed immediately before use. It was diluted to 2 ml and filtered through 0.22 µm filter
before 100 µl of the filtered sample was loaded onto the FPLC Mono Q column preequilibrated with 10 mM Tris, pH7.8 buffer. 10 ml of the buffer was used to allow all
neutral and positively charged species to elute out of the column. The salt concentration
in the buffer was increased to 500 mM (10 mM Tris and 500 mM NaCl), and 35 ml was

used to elute negatively charged species, 10 ml of the starting buffer was used to reequilibrate the column. Flow rate used was 0.5 ml/min. Five peaks were obtained. The
first two peaks were the major peaks and appeared at the beginning, before the salt was
passed through the column.

The other relatively small three peaks eluted at salt

concentrations of96 ± 13, 129 ± 9, 154 mMNaCl, respectively (n = 8).
2.4.3.1

FPLC Purification of GST Protein
The glutathione affinity purified GST was loaded onto a Mono Q HR.5/5 column

pre-equilibrated with 10 mM Tris pH 7.8. A salt gradient was created using 10 mM Tris
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pH 7.8 as buffer 1 and 10 mM Tris, 1 M NaCl, pH 7.8 as buffer 2. Used 10 ml of buffer
1 (salt concentration at 0 mM) to allow all neutral and positively charged species to elute
out of the column. Mixed buffer 1 and buffer 2 to give 500 mM salt concentration, and
maintained for 25 ml to elute the GST protein, increased to 1 M NaCl and stay there for
5 ml to elute any remaining material off the column. Returned to buffer 1 to re-equilibrate
the column. The flow rate used throughout the program was 0.50 ml/min.
2.4.3.2

FPLC Purification of a-Spectrin Peptides
The glutathione affinity purified spectrin peptide was dialyzed against 40 mM Tris

pH 7.5 buffer. The dialyzed spectrin peptide was loaded onto a Mono Q HR5/5 or
HRl0/10 column pre-equilibrated with the 40 mM Tris, pH 7.5 buffer. Two buffers were
used to create a salt gradient, buffer A, 40 mM Tris pH 7.5 with no salt and buffer B, 40
mM Tris pH 7.5 containing 500 mMNaCI. All peptides except for Spa 1-49, Spa49-167
and Spa 1-446 were purified using the following procedure: The salt concentration
remained at 0 mM for 40 ml to elute all neutral and positively charged species off the
column. The gradient was increased to 125 mM NaCl after 40 ml and to 155 mM NaCl
after another 50 ml to elute the spectrin peptides. The salt concentration was increased
to 500 mM NaCl to clean the column before re-equilibrating it with buffer A The flow
rate used was 2 ml/min.
The following procedure was used for Spa 1-49: 10 ml buffer A to elute neutral
and positively charged species off the column. The gradient was increased to 300 mM
NaCl after 50 ml to elute Spa 1-49 before increasing it to 1 M to clean the column. The
column was finally re-equilibrated with starting buffer. The flow rate used throughout the
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program was 0.50 rnVmin.
Affinity purified Spa49-167 contained another peptide that elute at the same
position when the above program was used. Thus a slower gradient was required to purify
this peptide. The following procedure was used: 40 ml of buffer A to elute all neutral and
positively charged species off the column. The gradient was increased to 100 mM NaCl
after 10 ml and remained at that concentration for 55 ml to elute the contaminating band.
Spa49-167 eluted by increasing the salt concentration after 20 ml to 125 mM NaCl
followed by another increase after 50 ml to 155 mM NaCl. The column was cleaned by
increasing the salt concentration to 500 mM NaCl before re-equilibrating the column with
buffer A The flow rate used throughout was 2 rnVmin.
Spa 1-446 was purified using the following procedure: 40 ml buffer A to elute
neutral and positively charged species. The salt concentration was increased to 13 5 mM
NaCl and remained constant for 120 ml to elute other contaminants. Spa 1-446 was eluted
by increasing the salt concentration after 24 ml to 175 mM and keeping it constant for 64

ml. The column was cleaned by increasing the salt concentration to 500 mM NaCl before
re-equilibrating the column with the starting buffer.

2.5

Protein Gel Electrophoresis

2. 5 .1

Sodium Dodecyl Sulfate Polyacrylamide Gel Electrophoresis (SDS-P AGE)
The SDS-PAGE was done according to the method of Laemmli (Laemmli, 1970)

with modifications using the Bio-Rad (Richmond, CA) mini-protein II electrophoresis cell.
The lower separating gel consisted of380 mM Tris, 0.1% (WN) SDS, 0.033% (WN)
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ammonium persulfate, 0.067% (VIV) TEMED(Bio-Rad, Richmond, CA), and pH 8.8 with
the acrylamide varying between 3-16% (WN) and the N,N'-methylene bisacrylamide
varying between 0.08-0.43% (WN). It was made by adding the appropriate amounts of
4X buffer (1.52 M Tris, 0.4% (WN) SDS, pH 8.8), 10% (WN) ammonium persulfate,
30% (WN) acrylamide-0.8% (WN) N,N-methylene bisacrylamide solution, TEMED, and
autoclaved deionized water. The upper stacking gel consisted of 3. 9% (WN) acrylamide,
0.1 % (WN) N,N'-methylene bisacrylamide, 125 mM Tris, 0.1 % (WN) SDS, 0.05%
(WN) ammonium persulfate, 0.1% (VN) TEMED, and pH 6.8. It was made by adding
the appropriate amounts of 4X buffer (500 mM Tris, 0.4% (WN) SDS, pH 6.8), 10%
(W/V) ammonium persulfate, 30% (WN) acrylamide-0.8% (WN) N,N'-methylene
bisacrylamide solution, TEMED, and deionized water. Gel thickness was made 0. 75 mm
by using 0.75 mm spacers. Gel samples were prepared by adding equal volume of protein
sample and 2X sample buffer containing 125 mM Tris, 20% glycerol, 4.1% (W/V) SDS,
2% (V/V) P-mercaptoethanol (PME) and 0.001% Bromophenol Blue, pH 6.8 followed
by boiling the sample for 5 minutes. Sample size ranged between 1- 25 µl depending on
the peptide concentration (0.1-10 µg of peptide). Molecular weight standards (the low
molecular weight standards: ovalbumin (43.0 kD), carbonic anhydrase (29.0 kD), Plactoglobulin (18.4 kD), lysozyme (14.3 kD), bovine trypsin inhibitor (6.2 kD) and insulin
(a and

p chain) (2.3 and 3.4 kD, respectively), or the high molecular weight standards:

myosin (H-chain) (200 kD), phosphorylase B (97.4 kD), bovine serum albumin (68.0 kD),
ovalbumin (43.0 kD), carbonic anhydrase (29.0 kD), P-lactoglobulin (18.4 kD) and
lysozyme (14.3 kD) were used. Gels were ran in a buffer consisted of25 mM Tris, 192
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mM glycine, and 0.1% SDS at a range of 120-160 V. Electrophoresis was stopped
when the dye front reached -0. 5 cm from the bottom of the gel (40-7 5 minutes depending
on the percentage of acrylamide in the gel-4%-16%).
2.5.2

Non-Denaturing Polyacrylamide Gel Electrophoresis
Bio-Rad (Richmond, CA) mini-protein II electrophoresis cell was used to run the

non-denaturing PAGE. Separating gel, stacking gel, and electrophoresis buffer were the
same as those for SDS-PAGE but contained no SDS. Sample buffer also contained no
SDS or

PME.

Gel thickness was 1.5 mm. All other conditions were the same as those

for the SDS-PAGE.
2.5.3

Coomassie Blue Staining
Both SDS-PAGE and non-denaturing-PAGE were stained in the same way. After

running the gels, they were immediately transferred to a petri dish containing fixing
solution (40% (VN) methanol, 10% (VN) acetic acid) and left on a rotator for 2 hours
(-60 rpm). The gels were transferred to another petri dish containing the staining solution
(0.05% (WN) Coomassie Blue R-250) and left on the rotator for another 2 hours. After
that the gels were transferred back to the fixing solution for destaining. The destaining
solution was changed several times until destaining was complete. The number of changes
and the time of destaining differed depending on the type of gel and the percentage of
acrylamide. Non-denaturing gels required extensive (- 1 day) destaining. The gels were
then stored in 5% acetic acid before drying.
2.5.4

Silver Staining
Silver staining was done according to published literature (Merril et al., 1983).
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After running a gel with 10 - 300 µg of samples per well, the gel was placed in fixing
solution (20% (w/v) trichloroacetic acid) for one hour. The gel was washed twice with
washing solution (10% ethanol, 5% acetic acid), the first for 10 minutes and the second
for 20 minutes. The gel was placed in a soaking solution (3 .4 mM potassium dichromate,
3.2 mM nitric acid) for 5 minutes before staining it in 12 mM silver nitrate solution for 20
minutes. The gel was moved to the developing solution (0.28 M sodium carbonate, 0.05%
(v/v) formaldehyde) and agitated for 2 minutes. Fresh developing solution was added and
the gel agitated until slight yellow background appeared. The gel was placed in stopping
solution (3% (v/v) acetic acid) for 5 minutes before it was washed twice with deionized
water and stored.
2.5.5

Molecular Weight Determination
Both coomassie blue and silver stained gels were dried using either a Bio-Rad

model 543 gel dryer (Richmond, CA) or by air drying. The coomassie blue stained gels
were scanned on an ISCO model 1312 gel scanner and analyzed using a commercially
available software (Chemresearch Chromatographic Data Management Software, ISCO,
Lincoln, Nebraska). Using this program, the distance traveled by molecular weight
standards were plotted against the log of their molecular weight. Using the relation:
d =blog MW+ c
where d is the distance traveled by the band, MW is the molecular weight of the standard
and band care constants, linear fitting was used to determine the values ofb and c. With
b and c known, the distance of each peptide's band was plugged in the equation to give the
estimated molecular weight.
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2.6

Western Blotting
After running SDS-P AGE or non-denaturing-PAGE, if necessary, gels were

prepared for blotting by soaking them in the transfer buffer (25 mM Tris, 192 mM glycine,
20% methanol, pH 7.5). The blotting was done using blotting paper (USB, Cleveland,
Ohio) at constant voltage of 22 V overnight at 4 °C. After blotting, the blotting papers
were soaked in TBS buffer (5 mM Tris, 150 mM NaCl, pH 7.4) containing 9% non-fat
milk with shaking for 1. 5 hours at room temperature. Then blotting papers were soaked
in the primary antibody solution with shaking for 1.5 hours at room temperature. Two
different mouse antispectrin monoclonal antibodies (SB-SPl and SB-SP2, Sigma Chemical
Company, St. Louis, MO) and a rabbit antispectrin polyclonal antibody (Sigma Chemical
Company) were used throughout the study. Blotting papers were washed with TBST
(TBS containing 0.05% Tween-20) buffer three times for 5 minutes each. After that
blotting papers were soaked in the secondary antibody (Goat anti-mouse for SB-SPl and
SB-SP2 antibodies and Goat anti-rabbit for the polyclonal antibody, Pierce, Rockford, IL)
with shaking for 1.5 hours at room temperature, and washed 4 times with TBST for 5
minutes each. After that the developing solution (100 mM Tris, 100 mM NaCl, 5 mM
MgCl:o 0.4 mM 5-Bromo-4-Chloro-3-Indolyl Phosphate p-Toluidine Salt, 0.4 mM Nitro
Blue Tetrazolium, pH 9.5) was added, and blotting papers were shaken gently until bands
appeared to desired intensity, followed by washing twice with deionized water for 2
minutes each and air drying.
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2.7

Molecular Weight Calculations
Molecular weights of spectrin peptides were determined from amino acid contents

using the program PEPTIDESORT, Genetics Computer Group. Molecular weights of the
following spectrin peptides: Spcx 1-49, Spcx 1-155, Spcx 1-167, Spcx 1-446, Spcx4 l- l 55,
Spcx41-167, Spcx41-273, Spcx49-155, Spcx49-167, Spcxl00-255 and Spcxl00-273 were
found to be 5.8, 18.4, 19.9, 51.7, 13.6, 15.1, 27.3, 12.7, 18.3 and 20.6 kD, respectively.
The molecular weight ofSpcx 1-166 (S12C) was 19.8 kD. The molecular weight of 26 kD
for GST was obtained from literature (Smith and Johnson, 1986). The molecular weights
of fusion proteins were calculated by adding the molecular weight of the spectrin peptide
to the molecular weight of GST. Molecular weights of ex-and P-spectrin were obtained
from literature to be 280 (Sahr et al., 1990) and 246 kD (Winkelman et al., 1990),
respectively. 215, 89, 78, 72, 43 and 35 kD were used as molecular weights of bands 2.1
(ankyrin), 3, 4.1, 4.2, 5 (actin) and 6 (glyceraldehyde-3-phosphate dehydrogenase),
respectively (Mathews, C.K. and Van Holde, K.E., 1990).

2.8

Amino Acid Sequencing
After running SDS-PAGE, gels were prepared for blotting by soaking in transfer

buffer (10 mM CAPS, 10% methanol, pH 7.5). The blotting was done using polyvinylidine
diflouride membranes (Applied Biosystems, Foster City, CA) at 0.15 Amp. for 1 hour.
The membranes were stained in 0.05% Coomassie Blue solution for 5-10 minutes and
destained in 40% methanol, 10% acetic acid solution for -10 minutes. They were rinsed
in deionized water for 2 minutes and left to air dry. The desired bands were excised and
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sent for amino acid sequencing.

Protein Concentration Assay

2.9

Peptide concentration for spin labeled samples was determined by a dye binding
assay (Bradford, 1976). The dye solution was prepared by diluting the dye reagent
(Coomassie Brilliant Blue G-250, Bio-Rad, Richmond, CA) five times by adding 4
volumes of deionized water to one volume of the dye reagent followed by filtering the
solution through a Whatman filter paper. Five BSA standard solutions were prepared with
concentrations ranging from 0.2 - 1 mg/ml. 100 µl of protein samples (standards or
spectrin) were added to 5 ml of the dye solution. These solutions were left to stand at
room temperature for 5 minutes before the absorbance at 595 run were measured, using
the dye solution as blank. Absorbance of the standard solutions were plotted against their
concentrations. Least square linear fit was used to obtain the best fit calibration equation.
Concentrations of the spectrin peptide solutions were determined from the calibration
equation.

2.10

Stability of a-Spectrin Peptides

2.10.1

Degradation
Spectrin peptides were tested for degradation by incubating the FPLC purified a-

spectrin peptide at -70, -20, 4, 25 and 35 °C and taking SDS gel electrophoresis samples
at time zero and after 24 hours. These samples were electrophoresed as described in
section 2. 5 .1 above. The gel was then studied for any degradation bands.
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2.10.2

Aggregation
FPLC purified spectrin peptide samples were incubated at 4 °C for 16-24 hours.

Non-denaturing gel electrophoresis samples were taken after incubation time. Also, after
incubation for 16 hours at 4 °C the sample was reloaded on FPLC to check if any
aggregation bands would appear.

2. 11

Limited Chymotrypsin Digestion
Chymotrypsin stock solution was prepared by dissolving 10 mg of 3X crystallized

bovine pancreatic a-chymotrypsin (Sigma) into 40 ml of 1 mM HCl solution. The stock
solution was stored in 200 µl aliquot at -70°C. The FPLC purified spectrin peptide was
concentrated using centricon micro concentrators (Amicon) to a final concentration of-1
mg/ml by centrifugation at 2000 xg on a Sorvall RT6000B Refrigerated Centrifuge and
an A500 rotor. A vial of chymotrypsin was thawed and added immediately to the reaction
vial in a ratio of 1 µl of chymotrypsin stock solution per 100 µg of spectrin peptide, i.e.
1:400 weight ratio. The time of chymotrypsin addition was considered as time zero. At
t= 0, 15, 30, 60, 90, 120, 150, and 180 minutes, a sample (about 50 µl) was removed,
equal volume of 2X SDS loading buffer was added and the mixture boiled for 5 minutes.
The samples were electrophoresed on SDS-P AGE.
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2.12

Spin Labeling and Electron Paramagnetic Resonance of cx-Spectrin

Peptides
2.12.1

Spin Labeling
The sulfbydryl specific nitroxide spin label 4-maleimido-2,2,6,6-tetramethyl-l-

piperidinyloxy (Mal6) was used to spin label a-spectrin peptides. It was purchased from
Aldrich Chemical Company Inc. (Milwaukee, WI) and used without further purification.
A 10-2 M stock solution was prepared by dissolving 25 mg of Mal6 in 10 ml of acetonitrile
and stored at -20°C.
In order to prepare a-spectrin peptides for spin labeling, PME was added to 3-5
mg of a-spectrin peptide to give a final concentration of 4 5 mM followed by incubation
at 4 °C for 30 minutes. The solution was loaded onto a Sephadex G25 gel filtration
column pre-equilibrated with 5 mM phosphate buffer at pH 7.4 (5P7.4) buffer. The first
peak containing the spectrin peptide was collected. It was concentrated using centricon
micro concentrators to a final concentration of -1 mg/ml. The second peak containing

pME was discarded.
The required amount ofMal6 spin label to give a molar ratio of24: 1 to the spectrin
peptide was transferred into a brown vial. Acetonitrile was removed by passing a very
gentle stream ofN2 gas to give a thin film of the spin label on the surface of the vial. The
spectrin peptide at 1 mg/ml was added to the vial and incubated at 4 ° C for 15 hours with
gentle stirring. After that, the mixture was loaded on the Sephadex G25 column preequilibrated with 5P7.4 buffer. The first peak containing the spin labeled peptide was
collected while the second peak containing the free spin label was discarded. The spectrin
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peptide was concentrated using centricon micro concentrators to a final concentration of
10-4 -10- 5 M. EPR samples were prepared by pipetting 20 µl of the spin labeled peptide
into a capillary tube. One end was sealed using a flame and centrifuged using an EIC
MICRO HEMATOCRIT MB CENTRIFUGE (DAMON IEC DIVISION, Needham
Heights, Mass) to push all sample to the sealed end.
2.12.2

Electron Paramagnetic Resonance (EPR)
EPR was done on a Varian E-Line Century series EPR spectrometer coupled with

a Zenith personal computer.

A commercially available software program, Assyst

(MacMillan Software) modified for EPR operation, was used for data acquisition and
analysis. Parameters used were: incident microwave power, 2 mW; center of the field,
3242.5 gauss; scan range, 100 gauss; modulation amplitude, 1 gauss; time constant, 0.128;
receiver gain, 1 x 104 ; scan time, 60 seconds. All experiments were done at room
temperature (-21°C). The spin labeled samples prepared as above were placed inside a
quartz tube containing silicon fluid situated within the cavity. Samples were left for 5
minutes in the cavity to equilibrate to room temperature before EPR spectrum were
obtained. Spin label concentration was determined by double integrating the EPR spectra.
Using the protein concentration assay mentioned above, the spectrin peptide concentration
was determined. Finally, the spin label to peptide molar ratio was calculated.
2.12.3

Calculations of the Rotational Correlation Time
The rotational correlation time was calculated using the equation:
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where ho is the amplitude of the middle peak, h_, is the amplitude of the high field
peak, h+ 1 is the amplitude of the low field peak and W0 is the peak-to-trough distance of
the center line (Fung and Johnson, 1984).

2.13

Purification of P-Spectrin Subunit

2.13.1

Preparation of Spectrin-Actin Network From Human Red Blood Cells
Packed red blood cells were obtained from a local blood bank (LifeSource). Up

to 120 ml of the packed red blood cells was used in each experiment. In each of 50 ml
centrifuge tubes, 5 ml of the packed red blood cells were placed and PBS7.4 buffer was
added. The tubes were centrifuged at 2000 xg for 4 minutes in a Sorvall R T6000B
centrifuge. The supernatant along with the huffy coat were aspirated, discarded and fresh
PBS7.4 buffer was added.

The centrifugation was repeated at least twice until a

completely clear supernatant was obtained. A low ionic strength buffer ( SmM phosphate,
lmM EDTA, pH 8.0) was added to the washed cells and centrifuged with SA600 rotor
at 16000 rpm for 10 minutes in Sorvall RC-SB centrifuge. The supernatant along with the
button at the bottom were aspirated and discarded and fresh buffer was added to the pellet.
The washing was repeated until the supernatant cleared completely of hemoglobin. The
white pellets from all tubes were combined and a 100 µl electrophoresis sample was taken.
Then 5 - 10 volumes of0.1 mM EDTA, 0.5 mM PME, 0.2 mM PMSF, pH 9.0 solution
was added and the mixture incubated at 37°C for 30 minutes.

The solution was

centrifuged at 22000 rpm for 60 minutes at 4 °C in an OTD65B Sorvall Ultracentrifuge
(Du Pont Instruments, Wilmington, D.E.) with T865 rotor. The supernatant (spectrin-
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actin network) was collected and the pellet discarded.
Preparation of Spectrin Dimer and Tetramer

2.13.2

The spectrin-actin was concentrated to -10 ml using Stirred Cells with a YM I 00
Disc Membrane. A I 00 µl electrophoresis sample was taken. The concentrated spectrinactin was loaded onto a Superose 6 column pre-equilibrated with 5P7.4 buffer and ran at
20 ml/hour. The first and the second peak containing the spectrin tetramer and dimer,
respectively, were collected and concentrated using Stirred Cells with a YMIOO Disc
Membranes.
2.13.3

Purification of (3-Spectrin From Spectrin-Actin Network

2.13.3.1

Purification of (3-Spectrin Using DE-52 Column

2.13 .3 .1.1

Purification of P-Spectrin Using Published Procedure

Published procedure was used to purify (3-spectrin (Speicher et al., 1992). The
spectrin-actin was concentrated to - 100 ml at - 0.6 mg/ml using Stirred Cells with a
YM 100 Disc Membranes. A 100 µl electrophoresis sample was taken. The concentrated
spectrin-actin was treated with solid urea, PME and IOX buffer (200 mM Tris, 1.5 M
NaCl, 10 mM EDT A, pH 8.2) to give a final concentration of 3M urea, 150 mM NaCl, 20
mM Tris, 1 mM EDTA and 0.6 mM PME. This solution was mixed batchwise with DE-

52 resin (Whatman, Fairfield, NJ) pre-equilibrated with 18 mM Tris, 3M urea, 135 mM
NaCl, 0.9 mM EDTA and pH 8.2 buffer (300 ml of resin per 100 mg of spectrin-actin).
The mixture was incubated for one hour at 4 °C before the solution was eluted with a flow
rate of 150 ml per hour. Three buffers with increasing NaCl concentrations were used to
elute proteins. The first one contained 152 mM NaCl and used to elute actin and other
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weakly bound contaminants. The second buffer contained 181 mM NaCl and used to elute
p-spectrin. The third contained 234 mM NaCl and used to elute a-spectrin. The Pspectrin fraction was concentrated using Stirred Cells with YM 100 Disc Membranes. The
concentrated sample was dialyzed three times against isotonic KCl buffer ( 10 mM Tris, 20
mM NaCl, 130 mM KCl, 1 mM pME, 30 µM PMSF, pH 7.4).
2.13.3.1.2

Purification of P-Spectrin Using Modified Procedure

The published procedure described above did not give P -spectrin with the purity
anticipated. The procedure was modified by using 135 mM NaCl to elute actin and other
weakly bound contaminants, 170 mM NaCl to elute P-spectrin and 500 mM NaCl to elute
a-spectrin.
2.13.3.2

Purification of P-Spectrin Using FPLC and Mono Q HR.10/10 Column
The spectrin-actin supernatant was concentrated to - 25 ml using Stirred Cells

with a YMIOO Disc Membranes and treated with urea buffer as above. The solution was
then incubated for 60 minutes at 4 °C and filtered through 0.22 µm filter and loaded onto
a Mono Q HR.I 0/10 anion exchange column of the FPLC system. The buffer system
consisted ofbuffer A(18 mM Tris, 250 mMNaCl, 0.9 mM EDTA, 3M urea, pH 8.2) and
buffer B (18 mM Tris, 400 mM NaCl, 0.9 mM EDT A, 3M urea, pH 8.2). The following
procedure was to purify P-spectrin: 50 ml buffer A to elute actin and other weakly bound
proteins. The gradient was increased to 287.5 mM NaCl after 10 ml and remained at that
concentration for 40 ml to elute P-spectrin. After that, buffer B was used to elute aspectrin. The flow rate used was 2 ml/min.
The P-spectrin peak at 100 mM NaCl was collected and concentrated using Stirred
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Cells with YMlOO Disc Membranes and/or centricon micro concentrators. P-spectrin was
dialyzed three times against isotonic KCl buffer (10 mM Tris, 20 mM NaCl, 130 mM KCl,
1 mM PME, 30 µM PMSF, pH 7.4) and used immediately or stored at 4 °C.

2.14

Stability of P-Spectrin

2.14.1

Degradation at 4 °C
Stability of P-spectrin was done by incubating J3-spectrin at 4 °C for 6 days. Gel

electrophoresis samples were taken at each day and stored at -20°C until all samples were
collected. SDS-PAGE was done on these samples.
2.14.2

Degradation at -70°C
Stability of 13-Spectrin was performed by taking a gel sample before freezing J3-

spectrin at -70°C for 3 months.

After thawing the stored sample, another gel

electrophoresis sample was taken. SDS-PAGE was done on both samples.
2.14.3

Aggregation at -70°C
This experiment was done as described above for the degradation except that non-

denaturing PAGE was done.

2.15

Radiolabeling of cx-Spectrin Peptides With

2.15.1

Time Study

125

1

The time study was done according to literature supplied by the company (Pierce,
Rockford, IL) in order to determine the labeling time that would give maximum labeling
and minimum degradation. 0.1 mCurie of 125I (1 µl) was added to 1 bead ofIODO-BEAD
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(Pierce, Rockford, II) in 100 µl oflabeling buffer (100P6.5). After stirring for 5 minutes
10 µg of Spa41-273 were added. At 0, 1, 2, 4, 8, and 16 minutes, 5 µl sample was taken
and added to 1 ml of PBS containing 0.5 mg/ml BSA. Each of the 6 samples was diluted
1:10 with 20 mM Tris, 1 mMEDTA, 0.5 mg/ml BSA, pH 7.4 by taking 100 µl of sample
into 900 µl of buffer. To the diluted samples, 100 µl of 60% trichloroacetic acid (TCA)
was added and the solution centrifuged. The supernatant from each sample was removed
into scintillation tubes. Fresh 50 µl of 60% TCA was added to the pellet and the solution
was again centrifuged. The supernatant was discarded and the pellets were placed into
scintillation tubes. Gamma counter (the Department of Biology) was used to count the
125

1 in pellet and supernatant samples. Table 1 shows counts per minute for the pellet

samples.
The counts per minute shown in Table 1 were plotted using the origin program
(Microcal, Northampton, MA) against time and shown in Figure 1. Figure 1 shows counts
per minute were maximum after 2 minutes of iodination. This indicates that iodination of
the spectrin peptide was maximum after 2 minutes, after which the peptide starts to
degrade under the reaction conditions. Thus all iodination for immunoprecipitation
experiments were done for 2 minutes to maximize iodination and minimize degradation of
spectrin peptides.
2.15.2

Radio labeling
To activate 1 mcurie of the 1251, 1 bead ofIODO-BEAD was added to the solution

followed by the labeling buffer (100 mM phosphate, pH 6.5) to 300 µ1 total volume. The
solution was stirred for 5 minutes and 100 µg of the spectrin peptide was added. The
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Table 1: Counts per minute for pellets for time study

TIME (min.)

CPM (pellet)

0

56088

1

60816

2

69294

4

62716

8

61268

16

55087
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Figure 1:

Iodination time study. Counts per minute of the pellets vs. minutes
of iodination of the spectrin peptide Spa41-273.
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mixture was then stirred for 2 minutes at room temperature before loading it onto
Sephadex G25 column pre-equilibrated with the labeling buffer. 1 ml fractions were
collected and counted. These counts per minute were plotted against tube number (Figure
2). The first peak contains the radiolabeled Spa 1-167 and the second one contains the
excess or free iodine. Tubes containing the radiolabeled peptide were determined from the
plot and grouped. The radiolabeled peptide was then dialyzed 3 times against isotonic KCl
buffer to further remove free iodine. Under reaction conditions, only tyrosine residues
would be labeled with iodine. According to the amino acid sequence of a-spectrin, the
peptide Spa 1-167 contains 5 tyrosine residues at positions: 35, 53, 81, 91, and 163.

2.16

Stokes Radius Determination

2.16.1

Column Calibration
A Superose 6 column attached to FPLC system was used to study the Stokes radii

of spectrin peptides. Before conducting the study, it was necessary to calibrate the
column.

Table 2 below show the 6 standard proteins (Pharmacia Biotechnology,

Piscataway, NJ) that were used to calibrate the column.
The Superose 6 column was pre-equilibrated with isotonic KCl buffer before
loading each of the 6 standard proteins. A flow rate of 0.20 ml/min was used to pass 30
ml of buffer through the column. The elution volume for each standard protein was
calculated.
2.16.2

Stokes Radius Calculations
The partition coefficients CK.av) for standards and samples were calculated using the
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Figure 2:

Radiolabeling of the spectrin peptide Spa 1-167 with
per minute vs. tube numbers are plotted.

125

1. Counts
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Table 2: Molecular weights (MW) and Stokes radii

(~)

of standards

used in Superose 6 calibration

PROTEIN

MW(kD)

Thyroglobulin

669

85.0

Ferritin

440

61.0

Catalase

232

52.2

BSA

67

35.5

Ovalbumin

43

30.5

Chymotrypsinogen

25

20.9

38
equation~.=

(V.-V0 )/(VcV0 ), where Ve is the elution volume, V 0 is the void volume and

Vt is the total bed volume.

supplied by the company.

v. is determined from the elution profile, V

0

and Vt were

K.i.. values for the standards were plotted against the log of the

Stokes radius (log (RJ). Linear regression was used to obtain the best fit for the equation
log (Rj = a K.i.. + b. After determining the constants a and b from standards, the equation
was used to calculate Stokes radii of spectrin samples.

2.17

Binding Assays of a-Spectrin Peptides Binding with P-Spectrin

2.17.1

Gel Filtration Assay
FPLC purified Spa 1-166 (S12C), Spa 1-167, spectrin-actin and P-spectrin subunit

were used in this study. All samples were dialyzed in isotonic KCl buffer before starting
the experiment. Spa 1-166 (S12C) or Spa 1-167 (1.15 x 10-6 Meach) was mixed with Pspectrin (2.7 x 10-7 M) and incubated for 24 hours at 4 °C. Control samples of Spa 1-166
(S 12C), Spa 1-167 or P-spectrin were prepared by adding the appropriate volume of
isotonic KCI buffer and incubated for 24 hours. After 24 hours, the incubation mixture or
control samples were loaded onto the Superose 6 column pre-equilibrated with the
isotonic KCI buffer. The same program used above for standards was used to obtain
elution profiles for the mixture and control samples. Kav was calculated and the Stokes
radii determined using the calibration curve. The Stokes radii were compared to check for
any change between incubation and control samples.
Binding constants were calculated by using the following equations:
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a-Sp +

P-spectrin

a-Sp-J}-spectrin (complex)

with the binding constant (Ka):

Ka= [a-Sp-P-spectrin]/ ([a-Sp][P-spectrin])

The area of the spectrin peptide of control and incubated samples were calculated.
The area of a peak was calculated by taking the two slopes and the base as a triangle and
using the equation
A= 1/2 x bx c
where A is the area of the peak, bis the length of the base and c is the height of the
peak (base to head of triangle). The percent of peptide remained was calculated by
dividing the area of the incubated sample by the area of the control sample. This percent
was multiplied by the initial concentration of the peptide to give the equilibrium
concentration of the peptide. The concentration of the complex was calculated by
subtracting the final from the initial concentration of the spectrin peptide. The equilibrium
concentration of P-spectrin was calculated by subtracting the concentration of the complex
from the initial concentration of P-spectrin.
2.17.2

Combined Western Blotting With Radiolabeling
P-spectrin was incubated with the radiolabeled peptide Spa 1-167 to give final

concentrations of9 x 10·7 and 3.5 x 10-7 M, respectively. Control samples of Spa 1-167

40
were prepared by adding the appropriate volume of isotonic KCl buffer. All samples were
incubated for 24 hours at 4 °C. After that samples were ran on 7% non-denaturing PAGE.
After Western blotting with the SB-SPl antibody, the stained bands (contained both

P-

spectrin and complex) and areas where the Spa 1-167 usually appeared were excised and
counted.
In order to determine the binding constant, the ratio of unbound to the total Sp a 1167 was calculated (counts per minute of the Spa 1-167 divided by the total counts per
minute). The equilibrium concentration of Spa 1-167 was calculated by multiplying the
initial concentration of the peptide by the ratios. The concentration of the complex was
calculated by subtracting the final from the initial concentration of the peptide. The
concentration of P-spectrin was calculated by subtracting the concentration of the complex
from the initial concentration of P-spectrin. The binding constant was then determined
from the equilibrium concentrations of the three components using the binding constant
equation (section 2.17.1).
2.17.3

Immunoprecipitation
P-spectrin was incubated with the radiolabeled Spa 1-167 to give final

concentrations of 3.3 x 10-7 Mand 1.26 x 10-6 M, respectively. Control samples were
prepared by adding appropriate volumes of isotonic KCl buffer to give a final volume of
5 µl. All samples were incubated for 36 hours at 4°C. Then 30 µg of the SB-SPl
antibody and 22 µl of immunoprecipitation buffer (20 mM Tris, 150 mM NaCl, 1% Triton
X-100, 1% sodium deoxycholate, 0.1% SDS, pH 7.5) were added and the solution
allowed to incubate for 1 hour at 4°C. Then 30 µl of Pansorbin (CalBiochem, San Diego,
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CA) were added, and the mixture was incubated for 30 minutes at 4 °C. The solution was
centrifuged at 15000 g for 3 minutes and the supernatant collected. The pellet was washed
3 times with 1 ml immunoprecipitation buffer by centrifugation at 15000 g for 3 minutes.
The 1251 in pellet and supernatant were counted and the counts per minute are summarized
in (table 3).
The binding constant was calculated by first determining the ratio of bound Spa 1167 from the total Spa 1-167. The ratio was determined by dividing the counts per minute
of the pellet by the total counts per minute of both pellet and supernatant followed by
subtracting the background ratio (control samples). The equilibrium concentration of the
complex was calculated by multiplying the ratio by the initial concentration of Sp a 1-16 7.
The concentration of the unbound Spa 1-167 was caculated by subtracting the
concentration of the complex from the initial concentration of the peptide.

The

concentration of P-spectrin was calculated by subtracting the complex concentration from
the initial P-spectrin concentration.

The binding constant was calculated from the

equilibrium concentrations of the three components using the binding constant equation
(section 2.17.1 ).

Table 3: Concentrations and molar ratios of Spa 1-167 and P-spectrin used in
immunoprecipitation experiments (Total volume, 18 µl)

Spal-167

P-Spectrin

(µmoles)

6.3 x 10-6

1.7 x 10-6

Concentration (M)

1.2 x 10-6

2.7xl0-7

Molar Ratio

1

0.3

CHAPTER III
RESULTS

3.1

Expression, Purification and Stability of GST and a-Spectrin Peptides

3 .1.1

Expression of GST and Spectrin Peptides as GST-Fusion Proteins
The HB101 E. coli cells were induced for the production of the fusion protein:

GST-Spcxa-b, where GST is glutathione-S-transferase, Spa is cx-spectrin, a is the amino
acid residue number in intact spectrin of the first amino acid in the peptide and b is the
amino acid residue number in intact spectrin of the last amino acid in the peptide. Cells
containing vectors of twelve different fusion proteins were prepared by Dr. Kelley: GSTSpcx 1-49, GST-Spa 1-155, GST-Spcx 1-166 (S12C), GST-Spcx 1-167, GST-Spcx 1-446,
GST-Spcx41-155, GST-Spcx41-167, GST-Spcx41-273, GST-Spa49-155, GST-Spcx49167, GST-Spcx 100-255 and GST-Spcx 100-273. These fusion proteins were expressed to
produce Spcxl-49, Spcxl-155, Spal-166 (S12C), Spal-167, Spcxl-446, Spa41-155,
Spa41-167, Spa41-273, Spa49-155, Spa49-167, Spa 100-255 and Spa 100-273.
SDS polyacrylamide gel electrophoresis results show that expressed proteins in
cells have correct molecular weights. Figures 3a show the results for GST-Spa 1-166
(S 12C). Lane 1 show the molecular weight standards. Lane 3 show the whole cell extract
ofHBIOl cells induced for the production of the fusion protein. Lane 2 show the whole
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Figure 3:

SDS polyacrylamide electrophoresis gels (12%) stained with 0.05%
Coomassie brilliant blue R. These gels (0. 75 mm thick) were run
for about 40 minutes under a constant voltage of 160 V. Lane 1 in a,
band c: low molecular weight standards; lane 2: total cell extract of

E.coli HBlOl without IPTG induction; lane 3: total cell extract of E.
coli HB 101 with IPTG induction for the production of the fusion
proteins (a) GST-Spa 1-166 (S12C), (b) GST-Spa 100-273 and (c)
GST-Spa 100-255.
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cell extract of E. coli without induction for the production of the fusion protein. The
molecular weight of the induced band was estimated using the molecular weight standards
as a reference and found to be 45 kD. Similarly, lane 3 in Figs. 3b and 3c showed induced
bands for the induction of GST-Spa 100-255 and GST-Spa 100-273 with estimated
molecular weights of 27 and 27 kD, respectively. The calculated molecular weights of
these fusion proteins were: 46, 44 and 47 kD, respectively. This shows that calculated
molecular weight matched the estimated value for GST-Spa 1-166 (S 12C) and not GSTSpa 100-255 or Spa 100-273. As shown above, calculated molecular weights for Spa 100255 and Spa 100-273 were 44 and 47 kD while the observed molecular weights were 27
and 27 kD, respectively. This molecular weight corresponds to GST and hence indicates
that DNA ligation was not successful and that the cells did not express the fusion proteins.
Several other attempts to express these two fusion proteins were not successful. Nine of
the proteins (GST-Spal-49, GST-Spal-155, GST-Spal-167, GST-Spal-446, GSTSpa41-155, GST-Spa41-167, GST-Spa41-273, GST-Spcx49-155 and GST-Spcx49-167)
were done by other members in our laboratory.
3 .1.2

Purity of GST and GST-Fusion Proteins
Fusion proteins were affinity purified from cell lysate with an average yield of 0.5-

7.0 O.D. values per liter of E. coli cell culture for all nine expressed fusion proteins except
for Spcxl-166 (S12C) which gave 10-15 O.D. units per liter. Some of these affinity
purified fusion proteins showed however other bands of lower molecular weights. Lanes
2 and 3 in Fig. 4a show SDS-PAGE of GST-Spcx 1-167 and Spa41-167, respectively,
while lane 1 shows molecular weight standards. Lane 2 in Figs. 4b, and 4c shows SDS-
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Figure 4:

SDS polyacrylamide electrophoresis gels (12%) stained with 0.05%
Coomassie brilliant blue R. These gels (0. 75 mm thick) were run for
about 40 minutes under a constant voltage of 160 V. Lane 1 in (a),
(b) and (c): molecular weight standards. Lane 2 in (a), (b) and (c):
glutathione affinity purified GST-Spa 1-167, GST-Spa 1-166 (S l 2C)
and GSTSpa41-273, respectively. Lane 3 in (a): glutathione affinity
purified GST-Spa41-167.
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PAGE of GST-Spa 1-166 and GST-Spa4 l-273, respectively, while lane 1 shows
molecular weight standards. The molecular weights of the fusion proteins: GST-Spa 1-49,
GST-Spal-155, GST-Spal-166(S12C), GST-Spal-167, GST-Spal-446, GST-Spa41155, GST-Spa41-167, GST-Spa41-273, GST-Spa49-155 and GST-Spa49-167 were
estimated to be 31±1, 41±2, 45 ± 2, 45 ± 2, 78 ± 4, 40 ± 2, 39 ± 1, 53 ± 2, 37 ± 2 and
39 ± 2 kD, respectively. Table 4 below show the estimated and calculated molecular
weights for these peptides.
In order to determine the best time for maximum thrombin digestion without

exposing the peptide to degradation fusion proteins above were loaded onto thrombin
column. Electrophoresis samples were taken between 0 and 31 hours from the start of
incubation and run on SDS-PAGE. It was found that after 24 hours the fusion proteins
were mostly digested. Figure 5 below shows SDS-PAGE with samples at 0 and 24 hours
(lanes 2 and 3, respectively). At 0 hours a major band with estimated molecular of 45 kD
that matches that of the fusion protein could be seen in addition to other bands with lower
molecular weight. After 24 hours the 45 kD band disappeared while a much fainter band
with estimated molecular weight of 15 kD appeared indicating the digestion of the fusion
protein and the production of the spectrin peptide.
3. 1. 3

Purity of 9 a-Spectrin Peptides Purified With Glutathione Affinity
Nine glutathione affinity purified peptides (Spa 1-155, Spa 1-166 (Sl2C), Spa 1-

167, Spa 1-446, Spa41-155, Spa41-167, Spa41-273, Spa49-155 and Spa49-167) were
used in this study. Six were used to determine the start of the structural domain of
spectrin. Spal-166 (S12C), Spal-167 and Spa41-273 were used in the study of the
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Table 4: Estimated and Calculated molecular weights of a-spectrin peptides in kD.
FUSION PROTEINS

ESTIMATED MW

CALCULATED MW

GST-Spa 1-49

31

32

GST-Spa 1-155

41

44

GST-Spal-166 (Sl2C)

45

46

GST-Spa 1-167

45

46

GST-Spal-446

78

78

GST-Spa41-155

40

40

GST-Spa41-167

39

41

GST-Spa4 l-273

53

53

GST-Spa49-155

37

39

GST-Spa49-l 67

39

40
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Figure 5:

SDS polyacrylamide electrophoresis gel (16%) stained with 0.05%
Coomassie brilliant blue R. This gel (0. 75 mm thick) was run for 1
hour under a constant voltage of 160 V. Lane I: low molecular weight
standard; lanes 2 and 3: GST-Spa4 l-167 incubated on the thrombin
column fort= 0 and 24 hours, respectively.
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head-to-head interactions. Glutathione affinity purified spectrin peptides were tested for
their purity on SDS-PAGE. Lane 2 in Figs. 6a, 6b, 6c and 6d show SDS-PAGE of the
affinity purified a-spectrin peptides Spal-166 (S12C), Spal-167, Spa41-167 and
Spa41-273, respectively. Lane 1inFigs6a-6d show the molecular weight standards. All
of the nine peptides purified by glutathione affinity exhibited one major band on SDSp AGE with molecular weights matching the calculated MW for these peptides. Minor
bands with estimated molecular weights that matches these of GST and corresponding
fusion protein were also detected (Fig. 6). Densitometric tracing show the intensity of the
major bands to be 60-95% of the total intensity in each sample. 0.5 - 5 O.D. units of
affinity purified spectrin peptides were obtained per 10 O.D. units of fusion protein loaded
on the thrombin column.
3.1.4

Fast Protein Liquid Chromatography (FPLC) Purified a-Spectrin Peptides

3.1.4.1

Assignment of GST Peak Using Affinity Purified GST Protein
Glutathione affinity purified GST was loaded onto Mono Q column. FPLC elution

profiles show two peaks. The first peak appears at 118 ± 14 mM NaCl and could not be
concentrated using a centricon-3 (3K MWCO) micro concentrator indicating molecular
weight ofless than 3000 kD. The second peak appears at 228 ± 4 mM NaCl and exhibited
as a single band on SDS-PAGE with molecular weight of26 kD, indicating that this was
the GST peak, obtained from literature.
3.1.4.2

Purity of Mono Q HRl0/10 Purified a-Spectrin Peptides
The net charges of the spectrin peptides Spa 1-49, Spa 1-166(S12C), Spa 1-167,

Spa 1-446, Spa41-155, Spa41-167 and Spa49-167 were determined from the program
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Figure 6:

SDS polyacrylamide electrophoresis gels (16%) stained with 0.05%
Coomassie Brilliant Blue R. These gels (0. 75 mm thick) were run for
about one hour under a constant voltage of 160 V. Lane 1 in a, b,
c and d show the molecular weight standards; lane 2 in a, b, c and d
show the glutathione affinity purified Spa 1-166 (S12C), Spa 1-167,
Spa41-167 and Spa41-273, respectively.
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PEPTIDESORT to be-1,

-s, -s, -33, -6, -5 and -7, respectively.

These charge values

could be grouped into three groups: the first contains peptide of 1 negative charge Spa 149; the second contains peptides of 5 to 8 negative charges Spa 1-166(S12C), Spa 1-167,
Spa41-155, Spa41-167 and Spa49-167 and the third contains peptide of 33 negative
charges Spa 1-446. Thus different salt concentrations were used for purifications. Figure
7a and 7b showFPLC elution profile for the purification of Spa 1-166 (S12C) and Spa 1167. Both Spa 1-166 (S12C) and Spa 1-167 were eluted at about 125 mM NaCl. Lane
2 in Figs. 8a and 8b show SDS-PAGE ofFPLC purified Spa 1-166 (Sl2C) and Spa 1-167
respectively, while lane 1 shows molecular weight standards. These gels show both bands
with estimated molecular weights of 20 kD, as expected. Figure 9a and 9b show the
densitometric tracing ofFPLC purified Spa 1-166 (Sl2C) and Spa 1-167 which show one
peak for each peptide.
During the FPLC purification of these peptides, when the salt concentration
increased sharply to 500 mM NaCl, a second peak, accounting for up to 80% of the total
eluted O.D. units, appeared. SDS-PAGE revealed that this peak consisted of Spa 1-166
(S12C) peptide, GST and the GST-Spa 1-166 (S12C).
3.1.5

Stability of a-Spectrin Peptides

3.1.5.1

Stability of a-Spectrin Peptides From Degradation
Spa49-167 incubated at -10, -20, 4 and 25°C for 24 hours did not show any sign

of degradation. At 35 °C, a faint band of lower molecular weight appeared (molecular
weight estimated to be 13 kD).
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Figure 7:

FPLC elution profile from Mono Q HRl0/10 column using a flow rate
of2 ml/min and sensitivity of 10 mV. a: the purification of Spa 1-166
(Sl2C); b: the purification of Spa 1-167.
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Figure 8:

SDS polyacrylamide electrophoresis gels (16%) stained with 0.05%
Coomasssie Brilliant Blue R. These gels (0. 75 mm thick) were run for
about 1 hour under a constant voltage of 160 V. Lane 1 in a and b
show the molecular weight standards; lane 2 in a and b show the FPLC
purified Spa 1-166 (S12C) and Spa 1-167.
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Figure 9:

Densitometric tracing of SDS polyacrylamide electrophoresis gels
stained with 0.05% Coomassie Brilliant Blue R. a: FPLC purified
Spa 1-166 (S12C). b: FPLC purified Spa 1-167.
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3.1.5.2

Stability of a-Spectrin Peptides From Aggregation
Spa49-167 incubated for 16 hours at 4°C exhibit

~

5% aggregation, smce

reloading sample to FPLC Mono Q column resulted in an elution profile with a major peak
and minor peaks (about 5%) eluted at 500 mM NaCl.

3.2

Purity and Stability of P-Spectrin Subunit

3.2.1

Analysis ofMembrane Samples on SDS-PAGE
0.76 ± 0.1(n=29) ml of white membranes were obtained per ml of packed human

red blood cells. Lane 1 in Fig. 10 shows SDS-Polyacrylamide gel electrophoresis of
membrane sample showing 7 main bands. These 7 bands were identified from literature
(Mathews, C. and Van Holde, KE., 1990) to be 1: spectrin (a-subunit); 2: spectrin (Psubunit); 3: band 3; 4: band 4.1; 5: band 4.2; 6: actin; 7: glyceraldehyde-3-phosphate
dehydrogenase. In the literature, they are usually labeled bands 1, 2, 3, 4. 1, 4. 2, 5 and 6.
3.2.2

Analysis ofExtracted Spectrin-Actin Samples on SDS-PAGE
Typically 1.2 ± 0.3 (n = 29) mg of spectrin-actin network were obtained per ml of

membrane or 0.8 ± 0.2 (n = 73) mg of spectrin-actin network per ml of packed red blood
cells. Lane 2 in Fig. 10 shows SDS-PAGE of a spectrin-actin sample which shows that
only spectrin (a- and

~-subunits

with approximately 1: 1 ratio), band 4.1 and actin.

3.2.3

Purity of P-Spectrin Subunit

3.2.3.1

Purified on DE-52 Column
In our hands, using published salt gradient with 152 mM (to elute actin), 181 mM

(to elute P-spectrin) and 234 mM (to elute a-spectrin) NaCl did not produce desirable
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Figure 10:

SDS polyacrylamide gel (7%) stained with 0.05% Coomassie Brilliant
Blue R. This gel was run for about 40 minutes under constant voltage
of 160 V. Lane 1: human red blood cell membrane; lane 2: spectrinactin sample; lane 3: 135 mMNaCl eluted peak; lane 4: 181 mM NaCl
eluted peak; lane 5: 234 mM NaCl eluted peak.
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results. The peaks eluted with 135 or 152 mM NaCl buffer showed bands of actin, 4.1,
P-spectrin and other proteins, as shown by SDS-PAGE (Figure 10). Lane 3 shows the
peak at 181 mM NaCl sample which shows a-spectrin band in addition to the P-spectrin
band. Densitometric tracing showed the percent area of a-spectrin to be 51 ± 10% and
P-spectrin to be 16 ± 5 % with some degradation bands accounting for the rest of the area.
The percent ratio of a- to P- spectrin bands was determined to be 24:76%. Lane 4 shows
the 234 mM NaCl peak sample which shows one band corresponding to a-spectrin
subunit. Densitometric tracing showed the percent area for a-spectrin to be 100% with
no detection of P-spectrin or any other protein. Using this weak anion exchange column
and under these published conditions, P-spectrin subunit could not be purified completely
free of a-spectrin while a-spectrin was eluted as a pure subunit. The published method
used four gel filtration columns in a series in the HPLC system.
This salt gradient was modified to 135 mM, 165 mM and 234 mM NaCl. It was
found that the 135 mM NaCl buffer was sufficient to elute actin and other weakly bound
proteins. Some P-spectrin eluted at this salt concentration. Densitometric tracing showed
26% of P-spectrin and 38% of actin. The peak eluted with the 165 mM buffer showed
the P-spectrin as the major band (88 ± 4% (n

= 5)), and a-spectrin as a very faint band (8

± 3% (n = 5). Thus the ratio of P-spectrin to a-spectrin is about 90: 10. Although this
ratio is better than that obtained following the published salt gradient, P-spectrin is still not
completely purified.

3.2.3.2

Purified on Mono Q HRl 0/10 Column
Purification using a Mono Q HRl Oil 0 anion exchange column and a salt gradient

69
produced three peaks at 250 mM, 287.5 mM and 400 mM NaCl (Fig. 11). The first peak
contained actin (36%), band 4.1 (4%) and other proteins as shown by SDS gel data (Fig.
12, lane 2). The second peak contained only P-spectrin (~100%) as shown by SDS gel
data (Fig. 12, lane 3) and analysis of densitometric tracings (Fig. 13). The third peak
contained a- (78%) and P- (16%) spectrin. Thus the ratio of the P-spectrin to the aspectrin in peak 3 was 83:17. About 0.06 ± 0.02 (n = 40) mg of P-spectrin was extracted
from 1 mg of spectrin-actin. About 0.04 ± 0.02 (n = 41) mg of P-spectrin was extracted
from 1 ml of packed cells.
3.2.4

Stability of P-Spectrin

3.2.4.1

Degradation of P-Spectrin at 4 °C
p-spectrin incubated in the presence of PMSF (serine protease inhibitor) at 4 °C

showed no significant degradation even after 6 days, as seen by SDS-gel data. However,
incubating P-spectrin for 6 days without the presence of PMSF showed 70% decrease in
P-spectrin.
Degradation of P-Spectrin From Freezing and Storage at -70°C

3.2.4.2

Freezing P-spectrin at -70°C, for up to 3 months, produced about 10% decrease
in P-spectrin.
3.2.4.3

Aggregation of P-Spectrin at 4 °C
P-spectrin was tested for aggregation at 4°C by running non-denaturing-PAGE

on P-spectrin samples incubated at 4 °C for 1 to 4 days. These samples were compared
with spectrin-actin samples.

P-spectrin appeared as one major band just below the

spectrin dimer band. No decrease in the intensity of the P-spectrin band was observed.
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Figure 11:

FPLC elution profile from a Mono Q HR.10/10 column at a flow rate
of2 ml/min and sensitivity of 10 mV. FPLC purification of P-spectrin

by increasing the salt concentration from 250 to 400 mM NaCl passing
by 288 mM NaCl where P-spectrin was eluted.
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Figure 12:

SDS polyacrylamide electrophoresis gel (7%) stained with 0.05%
Coomassie Brilliant Blue R. The gel (0. 75 mm thick) was run for
about 40 minutes under a constant voltage of 160 V. Lane 1: human
red blood cell membrane; lane 2: peak eluted at 250 mM NaCl; lane
3: peak eluted at 287.5 mM NaCl; lane 4: peak eluted at 400 mM
NaCl.
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Figure 13:

Densitometric tracing of SDS electrophoresis gel (7%) stained with
0.05% Coomassie Brilliant Blue R. The second peak on the FPLC
elution profile eluted at 287.5 mM NaCl salt concentration.
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Thus little aggregation of FPLC purified P-spectrin was observed after 4 days at 4 °C.
FPLC or DE-52 purified P-spectrin were loaded and ran on the Superose 6 column.
FPLC purified P-spectrin elute as one peak on the elution profile with Stokes radius ( 133
A), smaller than that of spectrin dimer, and assumed to be that of P-spectrin. However,

after incubating P-spectrin for five days at 4 °C, a small peak appeared at the void volume.
On the other hand, DE-52 purified P-spectrin elutes just after the void volume and has
much higher molecular weight than that of the spectrin dimer.
3.2.4.4

Aggregation of P-Spectrin at -70°C
P-spectrin samples frozen at -70°C for about 2 months exhibit little aggregation

as demonstrated by the elution profile of Superose 6, showing one peak with the same
Stokes radius obtained before freezing the sample.
Thus we have developed methods to obtain stable P-spectrin and a-spectrin
peptides.

3.3

Spectrin Domain Structure
The spectrin peptides Spa 1-155, Spa 1-167, Spa 1-446, Spa41-155, Spa41-167,

Spa41-273, Spa49-155 and Spa49-167 were used in limited chymotrypsin digestion
study. This work was done with other members in the lab and published. Refer to the
Appendix at the end of the dissertation for the published work.
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3.4

Binding of a-Spectrin Peptides to P-Spectrin Subunit

3.4.1

Gel Filtration Assay

3.4.1.1

Stokes Radius

3.4.1.1.1

StokesRadiiofSpectrinmonomer, dimer, tetramer, Spal-166 (Sl2C) and

Spal-167
Stokes radius of spectrin dimer and tetramer were found to be 158 and 229

A,

respectively, by Superose 6 column method. The Stokes radius for P-spectrin was 133

A. The Stokes radius for Spa 1-166 (S12C) was 30 A. The Stokes radius for Spa 1-167
was either 30 or 38 A, since two peaks appeared in the elution profile. Figure 14 includes
the elution profiles for Spa 1-166 (S12C), Spa 1-167 and P-spectrin. Another peak
appears in the P-spectrin elution profile and is probably a degradation peak.
3.4.1.1.2

Stokes Radius of P-Spectrin and Spa 1-166 (Sl2C) Incubation Mixture

Figure 14 includes the elution profile for the incubation mixture of P-spectrin
with Spa 1-166 (S12C) (0.1 mg of P-spectrin was incubated with 0.012 mg of Spa 1-166
(S 12C)). The calculated Stokes radii are summarized in table 5. A third peak was
observed with a Stokes radius of 141

A. Residual Spa 1-166 (S12C) exhibited same

Stokes radius (30 A). In addition, the area of the Spa 1-166 (S12C) peak decreased by
16%.
3.4.1.1.3

Stokes Radius of P-Spectrin and Spa 1-167 incubation mixture

Figure 14 includes the elution profile for the incubation mixture of P-spectrin
with Spa 1-167 (0.1 mg of P-spectrin and 0.012 mg of Spa 1-167). The calculated Stokes
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Figure 14:

Superose 6 gel filtration elution profiles of samples incubated in
isotonic KCl buffer for 24 hours at 4 °C. (a) P-spectrin. (b) Sp a 1-166
(Sl2C). (c) mixture of P-spectrin with Spa. 1-166 (S12C). (d) Spa. 1
167. (e) mixture of P-spectrin with Spa 1-167.
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Table 5: Stokes radius of the incubation the Spcx 1-166 (S12C) and P-spectrin controls

I STOKES RADIUS (A)

SAMPLE

PEAK

Spcx 1-166 (S12C)

1

30

P-Spectrin

2

133

Spcx 1-166 (S12C) + P-Sp

1

30

3

141
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Table 6: Stokes radius of the incubation mixture of Spa 1-167 and P-spectrin and controls

SAMPLE

PEAK

I STOKES RADIUS (A) I

Spal-167

1

30

2

38

P-Spectrin

3

133

Spa 1-167 + P-Sp

1

30

2

38

4

141
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radii are summarized in table 6. A third peak was observed with a Stokes radius of 141

A.

Residual Spa 1-167 exhibited same Stokes radius (30 and 38

A).

In addition, the area

of the two Spa 1-167 peaks decreased by 20%, respectively.
3.4.1.2

Binding Constants
The ratio of peak area in the incubation to that in the control sample was

determined to be 0.80 and 0.84 for Spa 1-167 and Spa 1-166 (S12C), respectively. The
equilibrium concentrations for the two mixtures were calculated (as described in section
2.17.1) and summarized in table 7. Binding constants of 6.3 x 106 and 2.1 x 106 M- 1 were
calculated for the peptides Spa 1-167 and Spa 1-166 (S l 2C), respectively.
3.4.2

Combined Western Blotting and Radiolabeling

3.4.2.1

Affinity of P-Spectrin and a-Spectrin Peptides to Spectrin Antibodies
Two monoclonal antibodies (SB-SPl and SB-SP2) and one polyclonal antibody

were used in this study. The three antibodies were tested for their affinity to P-spectrin
subunit and to the spectrin peptides Spa52-156, Spa 1-167, Spa 1-166 (S12C), Spa 1-446
and Spa41-273. Figure 15 show three western blots for the three different antibodies.
It could be observed that both SB-SPl and SB-SP2 monoclonal antibodies recognized P-

spectrin (to different degrees) and did not recognize any of the a-spectrin peptides. The
polyclonal antibody recognized P-spectrin and very weakly the a-spectrin peptides. The
monoclonal antibody SB-SPl was chosen since it shows stronger affinity to P-spectrin
subunit than SB-SP2 and since the polyclonal antibody would give some background on
the Western blots. Figure 16 shows SDS-PAGE of the same samples which shows the
presence and position of P-spectrin subunit and the a-spectrin peptides so it can be
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Table 7: Equilibrium concentrations for all three components in the incubation mixture
ofSpal-166 (S12C) or Spal-167 with P-spectrin.
SAMPLE

I Equilibrium Concentration (M)

Spal-166 (S12C)

9.7x 10-1

P-Spectrin

9.0 x 10-8

Spa 1-166 (Sl2C) + P-Spectrin

1.8 x 10-1

Spa 1-167

9.2 x 10-1

P-Spectrin

4.0 x 10-8

Spa 1-167 + P-Spectrin

2.3 x 10-7
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Figure 15:

Western blots of spectrin peptides and P -spectrin using the monoclonal
antibodies SB-SPI (a) and SB-SP2 (b) and the polyclonal antibody (c).
Lanes 1, 2, 3, 4, 5 and 6 in (a), (b) and (c): the spectrin peptides
Spa41-273, Spa 1-446, Spa 1-166 (S12C), Spa 1-167, Spa52-156 and
P-spectrin monomer, respectively. Lane 7 in (b) and (c): spectrin
actin.
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Figure 16:

SDS polyacrylamide electrophoresis gel (16%) stained with 0.05%
Coomassie brilliant blue R. This gel was run for about 1 hour under
a constant voltage of 160 V. Lanes 1, 2, 3, 4 and 5: glutathione

affinity purified Spa41-273, Spa 1-446, Spa 1-166 (S 12C), Spa 1-167
and Spa52-156, respectively. Lane 6: low molecular weight standards.
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compared to the western blot.
3 .4.2.2

Binding Between P-Spectrin and

125

1 labeled Spa 1-167

Figure 17 shows a Western blot of incubation mixture from two samples. The two
rectangles containing dark bands (top rectangles) are detected by the antibody SB-SPl and
thus contain P-spectrin. P-spectrin is present in these areas either as free P-spectrin or
as a complex with radiolabeled Spa 1-167. These areas were excised and counted. The
two bottom rectangles are the radiolabeled Spa 1-167 (free Spa 1-167) area and was also
excised and counted. Counts per minute for the P-spectrin area (combined P-spectrin and
complex) and for the Spa 1-167 area are summarized in table 8. The ratios of unbound
Spa 1-167 to the total Spa 1-167 for the two samples were calculated for samples 1 and
2 and found to be 0.37 and 0.42. The equilibrium concentrations of the three components
were calculated (section 2.17.2) and summarized in table 9. Binding constant of 2.3 ± 0.3
x 106 M- 1 (n = 2) was calculated.
3 .4 .3

Immunoprecipitation
The binding constant was calculated as described in section 2.17.3. The ratio of

bound Spa 1-167 to the total Spa 1-167 was calculated for both samples and found to be
0.24 and 0.16 after subtracting the background (table 10). Equilibrium concentrations
were calculated using these ratios and are summarized in table 11. Finally, binding
constants were calculated from the equilibrium concentrations and found to be 5. 7 ± 4. 3
x 106 M- 1 (n = 2).
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Figure 17:

Western blot of incubation mixture of radiolabeled Spa 1-167 with
P-spectrin from two samples.

The top two rectangles show

the stained P-spectrin and complex while the bottom rectangles
show the area where radiolabeled Spa 1-167 usually appears. These
four areas were excised and counted.
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Table 8: Counts per minute obtained for

~-spectrin

with complex bands and the

Spa 1-167 bands excised from Western blot.
SAMPLE

BAND

CPM

1

~-Spectrin

551

Spal-167

326

~-Spectrin

229

Spa 1-167

166

2
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Table 9: Equilibrium concentrations of all three components of mixtures
ofradiolabeled Spa 1-167 with P-spectrin.

Number

Sample

Equilibrium Concentration (M)

1

Spa 1-167

1.3 x 10-7

P-spectrin

6.8 x to-1

Spa 1-167 + P-spectrin

2.2 x 10-7

Spa 1-167

1.5 x 10-7

P-spectrin

7.0 x 10-7

Spa 1-167 + P-spectrin

2.0 x 10-1

2
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Table 10: Counts per minute for pellet and supernatant samples and calculated
ratios of the pellet to the total counts per minute.
SAMPLE

Number

CPM

CPM

RATIO

(PELLET)

(SUP.)

Pellet/
(pellet+ Sup.)

Spa 1-167

Spa 1-167 + P-spectrin

1

2830

5413

0.34

2

1676

4650

0.26

1

581

5236

0.1

2

921

8272

0.1
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Table 11 : Equilibrium concentration of all three components of the mixture
of radiolabeled Spa 1-167 with P-spectrin
Number

Sample

Equilibrium Concentration (M)

1

Spa 1-167

9.6 x 10·7

P-spectrin

3.0 x 10"8

Spa 1-167 + P-spectrin

3.0 x 10·1

Spal-167

1.06 x 10"6

P-spectrin

1.3 x 10·7

Spa 1-167 + P-spectrin

2.0 x 10-7

2
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3. 5

Spin Labeling

3.5.1

Purity of spin labeled Spa41-167, Spa 1-166 (S12C) and Spa41-273
Purified Spa41-167, Spa41-273 and Spa 1-166 (Sl2C) were spin labeled. SDS-

p AGE of these spin labeled peptides showed single band for each with estimated molecular
weight of 15 kD, 26 kD and 20 kD which matches those of the calculated values.
Densitometric analysis showed the percent area of the peptide band of all to be about
100%.
3.5.2

Molar Ratio of Spin Labeled Spa41-167, Spa41-273 and Spa 1-166

(S12C)
Spa41-167 contains one cysteine residue at position 167 which is the last residue

in the spectrin peptide. Conditions such as spin labeling incubation time and the amount
of spin label used were changed to obtain maximum spin labeling of this peptide.
Maximum spin label to Spa41-167 molar ratio of 0.5-0.8 was obtained for this peptide.
Spa4 l-273 contains two cysteine residues at positions 167 and 224. Spin label to
Spa4 l-273 molar ratio was found to be 1.2, which is about double the value obtained for
Spa41-167. Further, EPR spectrum shows two different populations of spin labels. This
indicated that both cysteine residues were being spin labeled.
Spa 1-166 (Sl2C) contains one cysteine residue that was introduced by site
directed mutagenesis at position 12. Spin label to Spa 1-166 (S12C) molar ratio was
determined to be 0.5 ± 0.03 (n = 3).
3.5.3

Motional Comparison of Spa41-167, Spa41-273 and Spa 1-166 (S12C)
EPR spectrum ofSpa41-273 show two populations of spin labels, one with slow
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motion and the other with fast motion (Fig. 18a). EPR spectrum of both Spa41-167 and
Spa 1-166 (Sl2C) show one population of fast motion (Figs. 18b and 18c).
EPR spectrum of the Spa 1-166 (S12C) peptide was compared quantitatively to
Spa41-167 and Spa41-273 by talcing the ratio of the peak to peak height of the high field
peak to the peak to peak height of the middle peak. The lower the ratio, the slower the
spin label motion. Table 12 summarizes the ratios obtained for the three peptides.
Rotational correlation time was calculated for the three peptides Spa 1-166
(Sl2C), Spa41-167 and Spa41-273 and found to be 1.8 x 10-10, 1.7 x 10-10 and 2.3 x io- 10
s, respectively. These values agree with the ratio of the peak-to-peak height of the high
field to middle field and summarized in table 12. It could be seen from table 12 that the
ratio of Spa 1-166 (S 12C) is higher than that of Spa41-273 and lower than that of Spa4 l167. The rotational correlation time of Spa 1-166 (S12C) is also higher than the rotational
correlation time of Spa4 l-167 but less than that of Spa41-273. This indicates a faster
motion for Spa 1-166 (S12C) than that of Spa41-273 and slower than Spa41-167.
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Figure 18:

EPR spectra obtained with 2 mW incident microwave power and a
scan time of 60 seconds. a: EPR spectrum of Sp a 41-2 73. b: EPR
spectrum ofSpal-166 (S12C). c: EPR spectrum ofSpa41-167.
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Table 12: Ratio of the peak-to-peak height of the third to the middle peaks in the EPR
spectrum
PEPTIDE

RATIO

Spa 1-166 (S12C)

0.41

Sp41-167

0.48

Spa41-273

0.32

CHAPTER IV
DISCUSSION

4.1

The First Human a:-Spectrin Structural Domain Begins with Serine
(From J. Biol. Chem. (1994) 269, 25955-25958. See Appendix.)
"The 106 amino acid sequence motifs of spectrin have been suggested to fold into

stable structural domains, consisting mostly of coiled coils of triple helices. With the
advent of molecular biology and biophysical techniques, structural studies of these spectrin
106-amino acid structural domains became approachable. However, one of the difficulties
in such an approach is determination of the correct phasing of the structural domains,
which may or may not coincide with the phasing of the sequence motifs.

Proper

identification of the domain phasing is vital to the construction of stable spectrin domains
for molecular studies. A previously published phasing shift for Drosophila a:-spectrin
indicated a downstream phase-shift of 26 amino acids for the structural domains
(Winograd et al., 1991 ). Using this phase-shift, we prepared recombinant spectrin peptide
with the sequence from residue 49 to residue 155 of human erythrocyte a:-spectrin and
found this peptide to be unstable relative to other peptides that we prepared. Using
several other recombinant a:-spectrin peptides and following the protease digestion
approach, we digested spectrin pepti~es with elastase and chymotrypsin and analyzed the

102

103
amino acid sequence of the digestive products. We provide the first experimental evidence
in identifying the first amino acid residue of the first spectrin domain in human erythrocyte
a-spectrin as residue 52 (Ser)".

4.2

Binding of a-Spectrin Peptides to 13-Spectrin Subunit
Two spectrin peptides were used in this part of the study, Spa 1-167 and Sp a 1-166

(S 12C).

The segment containing amino acid residues 52-156 are folded into triple

helical bundle. The N-terminal region (residues 1-51), though its structure is not clear,
interacts with 13-spectrin directly.
Three different methods were used to detect the binding between the 13-spectrin
subunit and Spa 1-166 (S12C) or Spa 1-167 in 10 mM Tris, 20 mM NaCl, 130 mM KCl,
1 mM 13ME, 30 µM PMSF, pH 7.4 at 4°C. These methods included the use of the gel
filtration method (Superose 6 column on the FPLC system), combined Western blotting
with radiolabeling, and immunoprecipitation.
4.2.1

Gel Filtration
The partial disappearance of the a-spectrin peak in the presence of 13-spectrin was

used as an indication of a -peptide-13-spectrin complex formation. Furthermore, the peak
areas of the a-peptide in the presence and absence of 13-spectrin were determined
quantitatively to obtain equilibrium concentrations of the a-peptide and of the complex.
The binding constants were found to be 2.1x106 M- 1 for Spa 1-166 (Sl2C) and 6.3 x 106
M- 1 for Spa 1-167, both at 4 C.
Gel filtration method was used to determine binding between the a I fragment
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(residues 7-639, which contains 5 domains with a molecular weight of about 80 kD) and
P-spectrin (Speicher et al., 1992). Binding constant was determined to be 4.5 x 106 M- 1
at 0°C.
4.2.2

Combined Western Blotting With Radiolabeling
In the combined Western blotting with radiolabeling method, the radiolabeled

peptide concentrations in both free form and bound to P-spectrin were detected
quantitatively. The average binding constant was determined to be 2.3 ± 0.3 x 106 M- 1 (n

= 2). This value is comparable to those obtained from gel filtration and to the published
value mentioned above.
4.2.3

Immunoprecipitation
This method has been used qualitatively in binding studies of different peptides

from a- and P-subunits of Drosophila spectrin (Viel and Branton, 1994). We have used
this method quantitatively on purified cx-spectrin peptides and P-spectrin subunit. As with
the combined Western blotting with radiolabeling method, the concentrations of the
complex were measured quantitatively from a mixture of the P-spectrin and the complex
in the pellet. The unbound peptide concentration was measured in the supernatant.
Binding constants, at 4°C, were found to be 5.7 ± 4.3 x 106 M- 1 (n = 2).
4.2.4

Comparison of the Three Binding Methods
Although these three methods provide similar binding constants, there are

differences between these methods.
The gel filtration method requires the measure of the difference in the ex-peptide
concentrations, obtained from peak area, in samples with and without P-spectrin. These
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two samples cannot be run simultaneously. Thus a great care is required in loading the
control and mixture samples to ensure identical experimental conditions.
In the combined Western blotting with radiolabeling, two components are being
detected thus eliminating the need for using controls in calculating binding constants.
However, this method is very laborious and requires a long time of processing samples
including blotting overnight. Also, it involves excising the spectrin peptide bands, which
are not stained and thus care is necessary in excising these areas of the Western blot. This
problem could be solved, however, using additional polyclonal antibody which recognizes
the a-spectrin peptides (although to a lesser extent) in addition to P-spectrin.
In the immunoprecipitation method both the unbound peptide and the complex are

being detected. However the presence of background binding of unbound peptide to the
antibody presents a source of error. The control sample is needed for calculating binding
constants. This method is the fastest of the three, and many samples can be processed at
the same time.
Although the three methods are different, the calculated binding constants,
appear to be in good agreement with each other, ranged between 2-6 x 106 M- 1 at 4 C.
These values are also in close agreement with the published value of 4.5 x 106 M- 1 for the
al binding to the P-spectrin subunit. Thus the binding of these two peptides to P-spectrin
resembles the binding of the al fragment to the P-spectrin. These peptides appear to be
a good model system for studying association properties of a p spectrin. Other workers
have found that P-spectrin-al equilibrium at the 37 C gave a binding constant of 1. 4 x 10 5

M- 1 (DeSilva et al., 1992). Binding was found to increase with decreasing temperature.
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The binding constant was found to be about 1x106 M- 1 at 30°C and further increased
to 4.5 x 106 M- 1 at 0°C. In addition, a cloned peptide with the first 158 N-terminal amino
acid residues gave a binding constant of 6.6 x 10 5 M- 1 at 30°C (Kotula et al., 1993).
Since the a I domain does not contain the first 6 amino acid residues, it was
determined that the removal of these residues did not affect the head-to-head interactions.
The removal of the next 10 amino acid residues decreased the binding by 50% (Speicher

et al., 1993). Cloned peptides that did not contain the first 27 amino acid residues did not
show any binding to the P-spectrin (Kotula et al., 1993). Peptides including the Nterminal amino acid residues of a-spectrin without the folding domain did not bind to

P-

spectrin. It was suggested that the first folding domain acts as a template for the folding
of the less ordered N-terminal residues and its presence is thus necessary for any binding
study.
Thus the use of the peptides used in this study as well as other modified peptides
may provide insights toward binding sites of head-to-head association in spectrin.
These peptides can be used as a model to represent the spectrin molecule. The head-tohead interaction region could be studied in a more detailed way. Deseases associated
with this area could be more understood with these models in hand. Our preliminary spin
label EPR results on the a-peptides indicate that EPR will be useful in obtaining both
binding and structural information on the N-terminal region of a-spectrin.

Conclusion
In summary, we have prepared spectrin peptides Spcx 1-166 (S12C) and Spcx 1-167
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to high purity while preserving their stabilities under experimental conditions. The Nterminal portion of these peptides (amino acid residues 1-51) are involved in binding with
the P-spectrin. The central portion (amino acid residues 52-156) fold into triple helical
bundles, while the remaining part (amino acid residues 157 - 166/167) is assumed to be
loosely folded. We demonstrate their binding abilities with the P-spectrin with three
independent methods. The binding constants were 2-6 x 106 M- 1 in isotonic KCl buffer at
4 ° C. Thus the two peptides can serve as a good model for a-spectrin, they include a
folding unit and have similar binding affinity to the P-spectrin subunit.
Now this system is poised for comprehensive studies to obtain structural
information of normal spectrin and to understand abnormal binding properties in spectrin
mutants.

APPENDIX
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and other ;iroc.eins that ;irovide• support to the lipid bilayer
and maintain• the ervt.hroc:yte nelClbility ! ll. Spectrin. which.
<ompn•es a· and '3-•ubunii:.s. ;ilay• a cntical role 1n maintain·
ing the architecture and therefore the inc.e~ty oi the red cell
membn.ne. :-.,{a.ny ilered.itary hemolytic anemias t.nvolve 5pe<:·
trin mutations i2-7'. In addition. sever3.l other proteins. 3uch
35 dystroph1n. a-11ct1n1n. ribnn. '!t.c .• 1hare man~ properties
nmilar to ti\ose of er,rthroc)"te spec~rin :ind are grouped a...s the
•pe<:rrin suoerfomi\y ( ll. ThtU. it is import:int to undent.:lnd
the structural proper-":1es oi spectnn. However. little !X;>eri·
mental infonnatton is available to descnbe the detailed thnedimensional .CrJcrure oi spectrin. Amino ac:td (8) and cDNA!9,
101 sequence anaJy5es of human eryth~ •pectrin (will be
referred to as human •pec::rin bereafter: other types of •pectrin
will b<! dearly •ta.tedl reveal that most part• of both •Ubun1t.s
consist of homo\0~11us 'equence motifs. Each motif conslsu of
abcJuc 106 arruno acids in len;th. Th!?re are :!2 5equence motifs
i.n tandem in the a·~ubunit and 17 sequence motif3 U\ the
13-subunit. Thue •equence motifs bave been sugge•c.ed to fold
into stable structural domains. consisting mostly of coiled coib
of :riple belices ( ll. 12l. With the advent of molecular biology
and biophysical techniqu'?s. structural studies of .::hese !pectrin
106-ammo acid struc:ural domains ispectnn domains! b«ame
ipproachable. Recently, :he <-ray •trUcture of a homodimer af
a 106-am.ino acid fragment in •egment l4 of Drosopnila. a-•pec·
mn has been published (13l. However, one o( the diffic:ulties in
such a.n approacb is to dee.ermine the cornet pbasing of the
•trUc:t:un..I doma.uu. which may or may not coincide with tb.e
pbasing of the sequence motifs.
Winograd et aL ( 141 provided experimental evidence from
DrosopAila a spe<:trin fral;meni:.s :0 •ugge5t a down.5tream
pba.se-shift of 26 amino acids for the •trucrun.l domaiD. such
that :be first amino scid in a folded unit is residue 26 in the
106-residue sequence morif.."'5summg human a·•pec:trin bas
the same pba.se-sb.ift as D.-o•o.onila a-spectnn. th.e fir>t amino
acid at the N·termmal end of the first nnictur:il domain !Ml)
·.vould be rosidue 49 'Leu l. since residue H I Ile' i• the first
amino acid oi the first •equence motif in human o-;peetrin I 9).
3ased an infonnation obtained from proc.ease protection anal·
ysis ( l2l. Speicher ec aL ( 151 •uggest thac structural domairus
beg;n and •nd around residue 30 of the sequence motif of
o-spectrin. Th••• phase-•hilt.s have be"n used :.o conscruct
stnictur.11 models or recombinant peptides. The Winograd
pha•e-shift ( 141 was u•ed to construct recombinant pepcides
either of a·•pectnn for x·ray studies 1 l3l or folding •tudies I 16)
or oi 13-spectrin for >upra-motif studies ( 171. The ph:ise-shitt af
dy!trophin ·.vas compared Mth Winogr:id"s phase·•hift in •pee·
:nn and was found :o be different by an upstream •hilt of 9
omino ocid• I 181. The Speicher ph:i••·•hift ( 121 w•s used to
constr.ic~ recombin.'.Jnt peptide! for spiec:nn utr:J.n'ler bindin5f
site studie• I 15 l. Kennedy et al. ( 191 st:ited th:it the phasintt of
~he .cnictur::il dom:nn m 13-specmn is shilled appro:<im>tely
~O-.JO res1due5 tow:ir-i :he C temunus compared 'N'lth the phas·
ing of the 3equence mot:fs.
:-lot only do differ~nt publi•hed re•ults •ugg~•t different
amino acids a.s A.Al for the •tr~c:ur:i.I domain. different num·
benng •y!Cems for the amino acids in the •peetrin sequence are
al•o tiled. 3efore :he ;iublic:ition of "'"'pectnn cDNA re•ults,
Glu was residue l ~ccording :.o Speicher and :.ia~hesi !201. The
human spectnn cDNA results detected 6 add.inonal amino
acid.. loc:ited u pstre:im of G\u to give MEQFPKE 3..5 the iinc 1
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Fie. l. Amino •cid sequence of human erythrocyte ~pec:tria from r"'Hidue 1 to 187. The cDNA numtMrin1 sywt.m ia shown and w.ed
throu~out Uus presenut1on. £Ian.a-'• 1 ~ l and chymotTYl>stn (•l N!'COfNtion tic.es an included. Uttdttrilntti ar1"01L•s1a.sun$Ju indicac. sir..s of
enryme cleavage u reporc.ed her-e. The amtno aad residues ;n the tlnt a·spKt.nn nT'Uct\lraJ dom&lll are sit.arUd.

amino acids in a·•pearin 19). Thus ~sidue l (Glu) in the prev;ou.s aumbering system (20> is now residue 1 in the cDNA
aumberillg system (91. Both aumb.,ring systems are u..ed in the
literature. altbou¢ not ne<:essarily clearly referenced. for all
types of spect:rin. Parry and co-workers <2ll identify the starting position of the tint scru=al motif as residue -46, uaing ti!"
aumberillg sysu.m of Sp<!icher and Mar<:hesi (20). Yan and coworkers ( 13) in tll"ir work on segment 14 of Dro•oplr.ila a•spectrin use the c:DNA numbering "Y•tem. w., follow th" cDNA
aumberillg syn.om in this ~port tFii;. ll.
Using '"veral r...:ambinant human a-sl>"Cttin P"Ptides and
1rrnograd
foUowuig the protease dig~scion 3pproach used by >
and co-,.orkers f 14 l. we provide the first experim.,ntal ev;d.,nce
in identifying the first 3m1no acid rosidue of the first spe<:trin
domain in a·sp.,ccnn. Prop<!r identific3tion of domain phasing
is vital to the construction of stab!" spectrin domains for molecular studies. Our r..sult.s show that the first spectnn struc·
tural domain suru W1th residue 52 !Seri tFig. ll.
!11.ATERW.S AND METHODS
Sp«tn.fl Rtt0mb11ta1tc Ptptld1.1-The cDNA done aJ that contain.

the N•t.enninal ~g1on

a(

the a*Jubunit 191, a !feneorou.s ('ift. of Dr. S. G.

Fo~t (Yale Un1ver."1C.:O' School of M~icine. :-.Sew Haven. CT1. wa1 lin·
Hnted ..,,t.h, Sacil 1.nd us~ ... a template. Oliconucleoude pnmer

contaJruo-c nquence r:vrT'5pondinJ to residue• t-9 of a·~Qeetnn. in a
'crue onent.u1on. a.nd pnmer cone.amine ,equenee eort'esponding to
re9iduu 159-167, 1.n an anllaenJI! onentauon. wen tynthfttzed by
N•aoo.aJ Bio9C1ences , Plymouth, ~tNl and used to make the spectnn
eoneQ"'Uct. o( a ~i>t1de W'lth the t,pquence of <J·tpectnn from t"e'1due 1 to
re11due tST <Spal-l6it 1 The published a•tp.ectnn Hquence 19) wu
UHd. Similarly• .!pitoetnn c:onnrucu ofSpa49-lS5 01nd Soo'49-167 were
Li.so ?rep~. Some o{ the oliconucleoude pnmen were 1ynthcs11ed by
the Weib Cent.er Oli11onuc:leoude Synthesu:er Labontory. The JJ>ec't?'ln
C1)nltruc:u were lipted into tbe BamHI .1.nd EcoRI StteJ of the (Jut.a•
~one S ·traruiense 1GSTJ eXl)resa1on \"Ktor ?C C:X·ZT f Pharmaaa Bioted:l tnc.l. These liJ&tions ••~ 1n.fr.sme wtth the GST protein. The
1

The abbr-eviattoru: use<i are: Spal-1Si. a.

~ot1de

Wlth

rhe uquenee

of a·'I~ from ru1due l to ~"du• 157 r11rnd:1r :ibh~Y1at1on system

u.se<I for other

l)e?t•du1: OST. rlutathione S-cr.insfen.n: F"?LC.
fut prot.ern llqu1d. ehrom•t.0(nol"ly: M 1. the fir3t am1,,o acid I t the
WU

N-t.enrunaJ end oft.he fi.nt. structural domain.

pGE:X-ZT vector eonta.1ns a. t.hrombin c:leava,e sic. betwffn GST and
the i.Q.Hn.ed geRe. i.1. s~n con1uuct. The speccna pepcidH wen
locstod in11J1edia!.t!ly foUoW1nf the thrombU. cleaYOC• si ... Tho exprution o( (wion protein wu under the c:oncrol of a /Jx pnnnoc.ar. Thu.a.
hitlh. inducible l•••ls of fuaion pro..iiu we.-. produced.
The ovft"1Jrociuced f'uslon tJT'OUtn 1GST·thrombin cleavage site--spec·
tria pepC'idot ..... l"'KOvered from: b•ct•ri.a.J lrsate and pUHd <JY..- a
1iutachion• •tnni~ column tf'••• rlur.athioa...seph•rvM 48 from Pbar.
maaa), uainc published method.s f 221. The column. with the bound
N.s1on protein. wu e.nen..11vely waahed.. followed by elution .,th buffer
conta.u:Unr fresh rlut.at.h1one. The spectria ~pcida .... cleaved from tbe
GST by immobili:i:ed tl\n>mb1n rel rCaJbiochem1 and eluted ...;th GST
a.ttd residual u.ncleaved fusion protein from the gel. The mixture wu
pused over the g!utatttione affinity colwnn again ta remove GST and
residual fu!lion protein to i'lv• relari¥ely pure spec'Cnn peptides. lC nee·
us.a.ry. the pe9ride:1 were further purified b~ faat proteia liquid chroma tnVilnhy l F"PLC1 W'\th a ~ono Q column 1 Phannac:iaJ. u.sinc 40 mN
Tris at pH i.5 and an NaCl indient.
E"-;t''"~ Di1ut1on and Prpridt St"qurncui..f-E:last.ue (nJm porcine
pan~as ISi(Tn&J in 5 mM Tris st pH S.O ..-as mixed .,,th 1 spirectrin
i>"Ptlde at a w•t~h< ruio o( l:l2.5. in 50 m." Tris at pH 8.8 and room
temperature. Samplu were ta.ken from the mixture at various time
pcnnu for gel electr0phore,1a analysis. Sin:ularly. ch~-mocryp11.a Cram
bovtne ?•ncreas <Sirma• tn 1 m.'4 HC1 was mixed .;th specinn peptide
at a Wf'•Jht ratio of 1:400' 14l. in 40 n:l'.\f Tri1 wtth 12.5 m"8 NaCl ac pH
i.S and room tempentutt. l?tr po•~•c-r:-·lam1de set elKtropho~tia •••
perfomu!•d us1nc ~l~troph.01""1!915 buffer cont:unin~ o..sc:;. sos. L.ow ra.nre
pra~tn molecular mua n.;indards I Life Tffh.nolof1es. Inc.J at 43.0. :29.0.
18.4. 14.3. S.2. and J.O kD• wore uaed to cu•d• th• mol~ar atLSS
ca.Jcu.lac.ion.. For amino aad :sequence analysis. polrvinyiiden• dilluondt
membnnes tApl)lied Sio,yst..ems. Foster City, CA» were uffd for elec·
troblotttnc. The 11m1no acid tequencinc of the d.icetuve product. was
done by the Uruven1ty of [!linots BioW'chnoloa C~nter.

RESL"1..TS A.'ID OISCt.'SS!ON

Using Winograd's down•cream phas.,.•hift of'.?5 3mino acids.
we designed Spa4~ 155. a P"Ptid" w;th lOi amino acid residu"s and with Ml at position 49. to be a P"Ptid" that included
the first stab!" structural domain of human a·sp.,ctrin. However, Spao19- l55 was found to be unstable wh"n compared to
the other Spa peptides that ,.;n b" discuss"d b.,low. The elec·
trophor.,cic gel of Spa4~ 155 purified by FPLC techniqu"s e:<·
hibited several bands. "'1th th• predominmting band at 12. i
kDa and two minor bands at about 9.8 and 8. 7 kDa cFig. 2A,
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~tri.a peptide-a.. ata.i.aed trtth Cooau.,,,.te arilllanc Blue.. A.:
ltvw f. F'Pt.C-puri.fied Spa"9-t55 !no '!i.uu.e preMnc.1: ta~:!. 10 ~
.ul.er ':.be tncroduec.oa of eia.su.M. at a pepad• to enzyme •eurrit r-auo of
t:!..S:l.; lan.t J. ~O imn: laiv 5. JO r::Un: La.iv 5. -40 cnJll: ian~ i. 50 cue.: lanf'
'· 50 tmn.. ~ 4. cnoll!'C'Ul.ar :nus .s~danfa. 3: la~ l. :?!..C·c~fied
Spa-49-167' (no eia.Jtue p~senci: ialf.f' 2. l :-t: !a.n~ J. :! ~: !artf' S. j h: lanf'
;, '4 !'\: .1..nd lanf' 7. 5 h. lan~ 4, ci;olK".Jlar 0'\8.55 itandardJ,

mo!eC'~lar

:nass for Spa49-l55 caic-.:iat•d irom <he
-=v@

b4!lie ..·e th~t ~h'" o;iajor band

•a.s to.hat of Spa49-t55 a.nd t~f! :iinor !l:ind.oe '''~!"'~ rror:-:. d~';"!"':l.·
dac1on prcduct.S of Spa49-l55. In :.he presenc!! of >?!asuse. at .i
wet~ht rar:o of l:!.:?.5 . .5pa49-L55 wa..s quickly dif{ened int0
t • to min. bands beio\\" t:.: ~D., ap·
low 1nti?nS1tles ·..,,::.h :::mc"...lrrent decrease tr\ the '.n·
i:..enstty of the t'.!. 7 -Wa ~3:id (fan.~ 1 !. •..\.5 i:.he dj~est.Jon ~ac:~on
'-Y'lth 1?ia.st.a.se proce~cieci tu~her. a. sc.e11dy decrease in -:.he in·
~nst:Y oi the t::?. 7-kDa band .1.nd an 1nc:-'!a.5e in. :::e :ntensltie~
of !he 1maller bandl were abser.~-!d 1 ian~s .1 md 5-7). At t l l 50
m1n. ~he hand at tZ.7 '.<Da w:is no lonq~,. 1-!tec<:.:ible but flint
bands below l'.!. 7 k.Da W'!r~ ...,siO~e {{artr 31. in cont.r3.St. under
!imi!ar cond.it.1ons. :he ~eoc.Ide 5pa49-L57 ....,u quite 3tabl-e.
Spa49-l67. '-Nit.h J molecular :-nass of l-4.:1 :.c..Da :::iiculated from
"...'i.e ,equence. aopear~d ~ a SU'l~ie band .lt. LJ.2 Wa on the sef
! ::i;. ~. !c:n~ ! l. :\..Jler :J: 50·min di~~st1on .....,,:n ~i:isuse under
:..""le condi:.10n5 iisted Jbovl? for Soa,.9-t55. :he Soa-t9-l6i di·
sest:on produc: 3.00~ar'!'d J.S .l s1ngie band at ~3.'.? 1<..Da iian~ :J).
~u ·:Jand ~rststed at : ':I '1 h 1 lan.~ J l. The intens1cy of ~his
::isnd dee:-e!\~eid Jt: • J h (lane 5L a.cpenreci as oniy J fame :,and
H: ~ --4 h ! lan~ .; ). :ind linaiiy ~C;J.me :iot detee~ble JC.! .. 5 !"\
(!aru 7). 1:'lu3 ~hese :iig~st1on ~suits SUOI6!5t Spa49-l57 ts
folded :nto .t :-nore st.1.bie :::on:lg".Jn.t1on :h.:in Spa49-t55 J.nd
:l::e raided Jtruc::u.r'! :-e:usts ~ias::J.Se digest1c::. T:,e ammo acid
~s1ciues ~eyonci t55 tn 5pa49-l57 ~rnV"lde ~i~ments :a tOid :he
p-eo~de into s more suole s::-.Jc::.;r~.
7:1e :?~C-puniied ~eotide Sea l-157. 'Vlth :i ~oi~lar
r:n11.s3 of ~9.9 "-.Oa <;:iiC"..iia~d :-Mr.1 :he sequenee. aooe11reci. J.3 a

smaller

f:-:l~enu ....\.t

~ared l :

2

or

J.O -

lartt I l. The

\J,j

J

!'-t-tenrun.al ua1no acid sequence a.nalysis.

- tJ.2

5.equenc:e was lZ. i k.Da. Thus.

=--1..iS

F°!C. 3. SOS-PACE 118".4: gel> al ?M>U:olync .::lice~tioa o( Spall67. naioe-d. wi.th Coom•Hie Srtlli•nl Slu-e. A. ei•.St.U<!! d.i11"t1on a(
Spa:1-l6i. l.Al't< l. molec:u.lar ma.as st.at\d&rds: !a.rt< :?. Spat-t67 Ina
~lut.a.5e present;. La~ J. ' n 1.fi..er ~..h. 1ntrodui:-;:ion a( elut.aae. at ..
~~ud• ·.o eru:yme ...,f!Hfht r.1uo of t:?.S: l. Sands at 16.0 .ind. t'.!..3 'illa
-~~ wed for !min.a •C"ld sequence a.nalyns. 3. =h.vmotr'Y1:Js1n difestion
o( Soal-l67. Lanr l, :nolKUiar ma.ss standards: larut !. Spal-167 fn.o
:.'iymotrr.u1n1: /a,,~ J. 90 min alter the :ntroduct1on o{ chymoc:nuin at
a. ~ptide ~ en:~e ""'•t!Jht r-aao
..tOO:l. Band a.c. 14.5 was used :or

---
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sinil• band at about 21.0 illa rFii. .'.IA, iaru '.!l. Zlas=e di·
;esrion of Spcd-tni <at we1-ght !"atlo o( l:!.2.5l r~sulted in ewo
Oa.nds at 16.Q and 12.3 k.Da at l • 90 min. These cwo bands
;:ier31st.ed 1n the digesuon mixture ac. t • 4 h t Fii. J.A.. lane J J
The b~nd intensity be-c:J.me undete~...able J.t t • 5 h ! not shown i.
Thes~ data SUiieSted that :he diiestton ?r'Oducts 'NI!~ very
st.able peptides "'ken compa~ ""th Spa49- L55 and had siln·
ilar subility u:i che dil!'estion p1'lduct ofSpa49-l6i, witic:h also
wtthstood elas<ase dil!'estion be~oad ~ b.
The N-U!nrunaJ sequence <Ula.lysi.s of the 12 . .3-lcDa fr-agmeat
"'"" found co be EDSYHLQVFK. .,.itich aliirne<i perfectly .,,th
50-59 i.n the a-spectnn sequence !Fil!'. ll. The ela..sta.se cle.avaie
rites around :.b.is region of a-1pect..-in coostst of residues 46
(Cly), 49 (t...uJ. and 52 (Serl, and cleavage ""'' at che C.ter·
minaJ end of :he pepode eon!lst ~f n!>idues tS l CGly), t54
(Leul.155CLeu1. !ST!AJa1. t5.~CLeuJ.and l64<'-iall. Wesu~~e•t
that elastas'! deav~d at 49 <LeuJ and ac. 157 'Alai to give the
?•Pride 5pa50-t57. which h:u a ca.Jcubted moleC'.ilar ::ias• of
L.2 ..3 kDa. r:,e first amino aCld at !he N ter.n1nus of :his di~es
eion :Jrociuet was dear!~ 50

1Gtu1. :is indiC3ted

~y i:he sequence

3naJysu d.:ic.a. However. the last amino actd at :he C-c.er.ninal
!nd ,,,as less eer'...atn and was su~gested by :nac..:hing gel ~lee·
trophore51s m.olee....iiar r.iasses with cak·.:iac.ed molec". .dar
:':"13SSe~. (t "NBS .JiSO p0!11S1bie that the digesCIOn pnxiuC: "Ml!..5
.3oa50-l54. Spa50-l55. or Spa50-l53. with c.:tlcuiat.ed :nolec·
ular masses o( ~2.5. LZ.6. ar t2.9 l<...Da. respe-c':ively. 7hu.s :he
::.i-i:.erm.1nal 'equence .Jnalys1s of the ~iasc.ase d...i.~!!st.lon pMduc:t
l l::?.3 l<.Dal of Spat-l67 sugge>ts that AAl is •1ther 50. j[. or
52. rr ..-\Al is 50 or 51. :hen :he first stable str.ic~ural domain of
human a·,oeco:nn is Spa50-l54 or Spa5 t-i.55. since ~he first
mot1f of a·!Oec:i'ln compn.ses LOS amino ac!d :'"~s1dues 1201. ·.vieh
.J moiecular :nass of !:2.5 or 1:2.S i<.03. resoee~:v~I~·. How~ver. '.Iii'~
found that :h~ elascase digestion product o( Soa49-LS3. a peptide ~hat •ncomoasses both 50-l54 •nd 5 i-l55. did not ;ired·
uce J.n;" i'eotldes 'N"lth >t."10tiity :Hmdar to :hose found in :he
di~est1on :>roducts of the other peptides ~h.Jc. "Ml? studied. -::-iis
piece of !V1dence sug~~sted th:it the C-ter.n1nal ~sidue of the
iint .str.Jc:urai dom31n was beyond t55. '•\"'! -:one!ude :hat :he
C-t.ennlna.l residue 13 lSO and ..l..A.l ls 52. ~-~Ytn~ ;i stable struc·
':.Ural dome.m of Spa52-l50. s~ed on this conclusion. 'Ne 5Ug·
~est that Spai-L5i contains .1 fully folded s::-..lc:ur.J..1 domain
wruch ts able ~ =-~'!'.St ~1:1Sta3e dil§'eStton. SL1sc.:ise will only
:ii~~st Spa 1-167 ;it sites pnor !O 5:! .ind .Jt1.e~ ~56 to t1''1? :he
d!g~st1on ;lroduc: 3pa50-t57. 'N"1th 3 molecular :nass of t.:?.3
'<..Dl!L. A..s discussed .i"oove. ~he diogestton ::iroduc! of Spa l-16i
a.pp~s~d J..S .i i:>l!Lnd at l'.!..S :.tDa f f"'i;. J.A.. iane J ).
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The N-t.ermmal •0<1uence oi t.he l6.0-k.Da i'nipnent '"""
found "' 0.. E:TA£E:IQERR•.,.,ruch >ii,.ned perfectly ·N1t.h "'""
due:s 19-23 in the cz·i'Pe'C";T1n 3equence. The ~la.st.a.3e deava~e
!ltt.es around t.hu re~on af (J-'!~r"!n con~ust ()f 17 (Val). t3
(l,..eul . .tnd ~1 IA.la/. The poss1ble ;JeOtlde'5 w~re 5pal9-l54,
Spal9-l55. Spal9-l57. or Spal9-l58. with caiculated molec·.i.lar :n~s~3 of 16.J. ~6...+. 16.5. or tl). T <.Da. ~5p-ec:wely. 'N~
1u~!:esc. ~h3.t :he ;>ept1de 1s ~tther .3pal9-t57 or Soal9-:5d.
Th.U ?eonde ;JroCably ::Jnt.a1n.s Spa l9-.5 t. the so-.::i.iled ·~efi.x
J.. I~'.:!!. which ts J.lso c::i.lied -~e!ix A· r l l l. ;>!us ~'ie :l.rst it.ab!~
:itruc:un..l domo.irl 3oa5:!-l56 Jnd re~1ciue lS-;'.
·n~ also ~~rt"or.netl cn:'""lotr"Y?s1n :ii~~s::1on U> oht...lJ.n inciependen:: di~l!SClon prociuc:.s from 5pal-l57 C~ymoc:·-:r?srn h1u
deava~~ :Htes diffe~nt ~·rom o:hose- or" elasuse. Alter '30 m.ln rJi
chymotf"Y?s1n d.li;est.100 \a: a. wetii;:-tt :-:i-c10 i)i L:400!. :.."i.e :;m~!e
hand oi" 5pal-~67 J.t :!LU k.Da :Fi~. JB. ~a:1~ 2) ;'!,ulted tn A
ba.od.3 :it or Oeiow '.?L•J k.Ds.. W"'\th :!-le 3mailesc one J.~ .1.0out l-.l..5
k.Da Ua1u J). Lne ~op band .it :!!.O '.<.Da wu ;issu.med to ':>e
und.ige!!ted 5pal-l67, while !he other fivf! wer? chymotr:r,::i51n
d.is;est10n ?roducu o( Spat- t67. :he :--f-ter.:iina! sequence inalysi:t of the sm3ilesc hand u l~.5 '.<..Da r!v~1ied in :imino ac.d
.. quenc• of KERVAE, :"'ruch :iJi,.ned perfectly "'1th posrnons 39
<Lys> chrou~h 44 iGlul of :J.·1pe<~-.n. l.'le ch.ymotr:-rp:un deavsg• """ around.:hts r~~on consl!ted otJ5 (T\TJ, JS I ?heJ, and
SJ fTyr1. J..'1d ~he deav1u;e 51te:t .it :he C·ternunal end of this
oeoe1de consisted of HO iTrni. tBO 1?he1. >nd l53 <Tyn 'l."e
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